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Abstract 
The present thesis describes the chemoenzymatic synthesis of ent-neopinone. 
The total synthesis of neopinone was accomplished in 14 steps from ~­
bromoethylbenzene. The synthesis began with a microbial oxidation of 
bromobenzene by Escherichia coli JM109(pDTG601) and features a Heck reaction, 
aldol condensation and a 1,6-conjugate addition. 
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1. Introduction 
An ideal synthetic target is one that incorporates structural complexity and 
utility. Such molecules provide chemists with interesting synthetic problems to 
tackle and allow for the development of new methods. Opium alkaloids fulfill these 
criteria as they have been used extensively in medicine for the treatment of pain. 
Despite morphine's small size, its complexity stems from the completely dissonant 
connectivity.1 Opiate alkaloids are harvested from opium poppy species grown in 
Iran, Afghanistan, Turkey and India. Because of the political unrest in these 
countries and the world wide demand of opiates, a short and efficient synthesis of 
morphine and its congeners is required. 
The Hudlicky group has a long history of exploring the development of a 
practical synthesis of morphine alkaloids. The current thesis will focus on a 
chemoenzymatic approach to ent-neopinone. Our current strategy relies on the 
construction of the C ring of neopinone from 3,S-cyclohexadiene-l,2-diol 6. This 
chiral building block is obtained from the biooxidation of ~-bromoethylbenzene 
using Escherichia coli JM109(pDTG601). We envision the conversion of diol6 to the 
homoallylic ethyl amine derivative 5, which will allow for the coupling of the A and C 
rings yielding a suitable precursor for the closure of the D ring intermediate via 
subsequent aldol condensation and 1,6-conjugate addition that should conclude the 
synthesis of neopinone (Figure 1). This thesis provides an historical overview of 
arene microbial oxidations and the use of these biooxidations in selected syntheses, . 
as well as a historical overview of opium alkaloids and selected syntheses. The 
1 
detailed description of our approach to ent-neopeinoine 1 comprises the discussion 
section of the dissertation. 
> > 
ent-neopinone 1 2 3 
< 
Figure 1. Retrosynthetic analysis for ent-neopinone. Morphine numbering and 
lettering shown. 
2 
2. Histrorical 
2.1 Microbial Oxidation of Arenes 
2.1.1 History of aromatic dioxygenases 
In early twentieth century, Stormer was the first to report the metabolism of 
aromatic substrates when he observed the bacterium Bacillus hexcarbavorum could 
use benzene and toluene for growth.2 Over half a century later it was shown that 
the products of this metabolism were catechols.3 In 1968, David Gibson published 
his seminal work on a bacteria (Psqudomonas putida) that utilized solely toluene or 
benzene as its carbon source.4-5 He showed that benzene and toluene were 
consumed at equal rates to that of oxygen consumption during metabolism. This 
suggested that the metabolic pathway did not proceed through the formation of an 
epoxide during the metabolism of arenes. To further investigate the possible 
mechanism, Gibson incubated cell extracts with proposed intermediates. Phenol 
and trans-dihydrobenzenglycol were metabolized slower than catechol and cis-
dihydrobenzene glycol. This led Gibson to propose a mechanism for the 
transformation of benzene to catechol shown in figure 2. 
lilt et°H ---I ........ ~OH ~OH 
7 8 9 10 
Figure 2. Proposed pathway for catechol formation by P. putida. 
3 
In order to confirm the proposed metabolic pathway and the evidence of the 
intermediate 9, Gibson began working with the bio-oxidation of substituted 
aromatics. When P. putida was incubated with p-chlorotoluene 11, two metabolites 
were produced, a catechol 13 and an unknown compound 12.5 When metabolite 12 
was subjected to acidic conditions it quickly decomposed to phenols 14 and 15 
(scheme 1). This degradation study as well as spectroscopic studies led to the 
proposal of (+ )-cis-4-chloro-2,3-dihydroxy-1-methylcyclohexa-4,6-diene 12. To 
confirm the hydroxyl groups of the catechol originated from one molecule of oxygen, 
1802 labeled oxygen studies were preformed.6 This confirmed his proposal for the 
incorporation of one molecule of oxygen for each molecule of substrate. 
¢ O2 [¢Cb] NAD+ ¢:OH .... ... ~ OH 
CI CI CI 
11 12 13 
! 
~ qOH ~ I + ~ I 
OH 
CI CI 
14 15 
Scheme 1. Proposed pathway for the metabolism of p-chlorotoluene by toluene-
grown cells of P. putida 
4 
In 1970, a mutant strain of P. putida was discovered that did not contain the 
genes encoding for the enzymes which are required to process the cis-
cyclohexandienediol.7 This allowed for the isolation of the diol in sufficient amounts 
so that stereochemical studies could be performed. Gibson was able to isolate what 
he believed to be (+)-cis-2,3-dihydroxy-1-methyl-4,6-cyclohexadiene 21 produced 
by the mutant strain (P. putida 39/D) when digesting toluene 20. Evidence at the 
time indicated that microbial metabolism of arenes proceeded through trans-
intermediates via hydrolysis of a cis-epoxide as shown in figure 3. 
16 17 
epoxide 
hyrolase 
.. 
OH 
~ OH U ----I ...... 
18 
Figure 3. trans-Diols resulting for hydrolysis of cis-epoxides 
19 
To determine the stereochemistry of isolated metabolite 21, the diol was protected 
as the diacetate and condensed with maleic anhydride. Hydrogenation of the Diels-
Alder adduct 22 produced the fully saturated tricycle 23 which was analyzed by 
NMR spectroscopy (scheme 2). 
5 
0 ~o~ o :: (x0H ii-iii iv o~O~ ... ... o ~ ... ~ OH OAe iii OAe 
0 o Hb 
20 21 22 23 
Reagents and conditions: i) P. putida 39/D; ii) AC20; iii) maleic anhydride; iv) H2, Pd/C. 
Scheme 2. Proof of relative stereochemistry of (+ )-cis-2,3-dihydroxy-l-methyl-4,6-
cydohexadiene 24. 
Analysis of the spectroscopic data confirmed that the vicinal protons Ha and Hb in 
compound 23 are in a cis configuration to each other. To determine absolute 
stereochemistry of the cis-hexadienediol, Gibson performed a hydrogenation of 21 
producing two diastereomers 24 and 25 (figure 3). Seperation of the diastereomers 
was performed with their monobenzoate derivates via column chromatography and 
subsequent ester hydrolysis provided the pure samples of the diastereomers 24 and 
25. Jones oxidation of 25 furnished the previously reported (-)-2R-methyladipic 
acid 26 and comparison of physical properties established the absolute 
stereochemistry of the cis-diol as lS,2R. 8 
(x:: : OH (x0H HO~OH ... CXOH + ... OH 0 
21 24 25 (R)-2-methyladipie acid 26 
Figure 3. Absolute stereochemical proof of the P. putida 39/D metabolite 21. 
However, through this stereochemical proof the stereo centers of the cis-diol were 
destroyed during oxidation. Thus the assignment was inferred from the facial 
6 
selectivity of the hydrogenation. It was not until Hudlicky's synthesis of PGEza in 
1988, that the absolute stereochemistry was proved unequivocally.9 
2.1.2 Isolation and characterization of the toluene dioxygenase 
The development of the mutant strain (P. putida 39/D) by Gibson allowed for 
the isolation of the gene coding for the enzyme responsible for the accumulation of 
the cis-cyclohexadienediols. This enzyme was coined toluene dioxygenase (TDO).10 
The nucleotide sequence of genes responsible for the metabolism of arenes was 
determined by thorough studies of mutant strains of P. putida11 (figure 4). This 
allowed for the expression of these genes in E. coli and helped confirm the metabolic 
pathway of the wild type strain. 
wild strain of Pseudomonas putida 
I 
R 
6 
R R 
toluene (x0H cis-dihydrodiol (x0H 
dioxygenase... -9' _d_e....;hy:....d_ro....:g:....e_na_s_e...... -9' __ L __ 
(todABC) ~ OH (todD) ~ I OH 
mutant strain t 
1 
.... acetate 
P. putida 39/D 
Br 
6 
I 
Br Br 
JM 1 09 (pDTG6~) (x0H JM 1 09 (pDTG6~) 6:0H 
(todABC) ~ OH (todABCD) I t OH 
JM 109 (pDTG602) J 
(todABCD) 
Figure 4. Metabolism of arenes by P. putida and recombinant strains of E. coli.1Z 
7 
The TDO genes were expressed in the recombinant E. coli JM109(pDTG601). 
This allowed for the over-expression of the TDO enzyme and thus the production of 
cis-cyclohexadienediols in sufficient amounts to be used sensibly as synthetic 
precursors. Other recombinant organisms JM109(pTDG602) and JM109(pDTG603) 
were created to allow for the production of catechols and 2-hydroxy-6-oxo-2,4-
hetpadienoates, respectively. 
The expression of the genes E. coli now allowed for these recombinant 
organisms to be used as tools in synthetic organic chemistry.13-14 The use of these 
recombinant E. coli organisms for biooxidations of arenes provides distinct 
advantages compared with the use of strains from P. putida. E. coli has been 
thoroughly researched and thus its growth conditions have been well optimized. P. 
putida requires the use of arenes as inducers for production of the desired enzymes. 
However the inducer is also a substrate and thus must be separated from the 
desired metabolite. In the recombinant E. coli, the inducer is a sugar analogue, 13-
isopropylthiogalactopyranoside (IPTG). Therefore eliminating the complication of 
having the inducer also be a substrate for the E. coli. Also the organism has been 
engineered with ampicilin resistances so it is robust and the cultures are not easily 
contaminated with other bacteria. The other advantage of the recombinant E. coli is 
the fact that it contains a plasmid, which has multiple copies of the genes 
responsible for the toluene dioxygenase allowing for greater expression and higher 
yields of diols. 
8 
2.1.3 Substrate scope and specificity 
Since Gibson's isolation of the first cis-cyclohexadienediol more than 400 
substrates of the toluene dioxygenase have been identified. Some of the best 
substrates are bromo-, chlorobenzene, styrene, naphthalene, m-dibromobenzene 
and ~-bromoethylbenzene. Despite the large number of metabolites only a fraction 
of these have been used in total synthesis.12 The dihydroxylations by TOO follow a 
predictable manner with respect to regio- and stereoselectivity. Boyd's research 
has allowed for the development of a model to account for the regio and 
stereoselectivity.15 The greater difference in relative size between the substituents 
(S and L) the higher the enantiomeric ratio of diol obtained. This model was later 
extended as shown in figure 5 to include larger, more conformationally flexible 
substituents, as well as taking into consideration substituents in the ortho and meta 
positions of substituted arenes. 16-17 
TDO 
.. 
Figure 5. Boyd's expanded model for the prediction of regio- and stereo selectivity 
of TOO dihydroxylations. 
9 
2.1.4 Applications of toluene dioxygenase in synthesis. 
In 1983, researchers at Imperial Chemical Industries were the first to exploit 
the cis-cyclohexadienediols in their preparation of polyphenylene 28 via a radical 
polymerization reaction (Figure 6).18 
~OH 
~OH 
27 
---I"'" tot 
polyphenylene 28 
Figure 6. ICI preparation of polyphenylene from cis-cycylohexadienediol. 
However, in the process of reforming the arene the diol functionality was 
deystroyed. The first stereochemical exploitation of the cis-cyclohexadienediols did 
not occur until Ley reported the synthesis of (+ /-)-pinitol 34 as seen in scheme 3.19 
(X0H ______ ~ ... ~OBZ ____ ii __ ~ ... ~OBZ + ~OBZ ~OBZ 
o 0:: ~ OH 
27 
OH 
MeoyYOH 
HO~OH 
OH 
(+/-)-pinitoI34 
29 20 31 
OH OH 
"''4IIIIIII-_v _ MeO~OBZ "''4IIIIIII-_iV __ MeoyYOBZ 
HO~OBZ ~OBZ 
OH 
33 32 
Reagents and conditions: i) PhCOCI, pyridine, DMAP, 0 °C-RT (84%); ii) m-CPBA, CICH2CH2CI, pH 8 
phosphate buffer (30 in 14%, 31 in 73%); iii) MeOH, camphorsulfonic acid (88%); iv) OS04, NMO, 
tBuOH/THF /H20 (61%); v) NEt3, MeOH, H20; 
Scheme 3. Ley's synthesis of( +/-)-pinitoI34. 
10 
In his synthesis he utilized the benzyl protected diol 29 to allow for facial selective 
epoxidation of the diene followed by selective opening of the vinyl epoxide with 
methanol. Installation of the remaining hydroxyls was performed by treatment of 
32 with OS04 followed by deprotection of the diol to yield (+I-)-pinitol 34 in 35% 
from benzene. The use of the diols to direct further transformations and the steric 
and electronic differentiation of the dienes are now standard strategies in the use of 
cis-cyclohexadienediols in synthesis. 
The first enantioselective application of cis-cyclohexadienediols was 
performed by Hudlicky in the formal synthesis of PGE2a 39 in 1988.9 The formal 
synthesis of prostanoid synthon 38, which was previously converted to PGE2a by 
Johnosn,2o was completed in only four steps; a vast improvement upon previously 
reported syntesis.12 As shown in Scheme 4, Transformation of toluene with 
Pseudomonas putida 39/D afforded the corresponding diol in a yield of 3 giL of 
culture. Protection of the diol as its acetonide gave compound 35. 
11 
0 i,ii ... (X°X iii .[~:xl ~ 0 
20 35 36 
~iV 
0 
[o::XJ< 1 QO 0IIIIIIIIIi 0)( 
38 37 
0 
0 QO ... ""'~C02H ... 
0)( § 
OH 
38 39 
Reagents and conditions: i) P. putida 39/D; ii) DMP, pTsOH, RT; iii) 03, MezS; iv) Alz03 (neutral), DME, 
reflux. 
Scheme 4. Hudlicky's formal synthesis of PGE2 •. 
Oxidative cleavage of the diene with ozone provided the ketoaldehyde 37 which 
underwent intramolecular aldol condensation to give the prostanoid synthon 38. 
This synthesis demonstrated the incredible value of the diol metabolites as chiral 
precursors for natural products or other synthetic targets. Research in the 
application of these metabolites as chrial synthons for synthesis has been lead by 
Ley, Banwell, Boyd and Hudlicky. The most significant contributions of these 
researchers will be presented in further detail. 
12 
In addition to Ley's synthesis of (+ / -)-pinitol 34, he also developed an 
enantiodivergent approach to (+)- and (-)-conduritol F 43 and 44.21 Starting for the 
same cis-cyclohexa-3,S,-diene-l,2-diol 27 as he used in his synthesis of (+ /-)-pinitol 
34, he treated the diol with dimethyl carbonate to form the cyclic carbonate 
followed by epoxidation with meta-chloroperoxybenzoic acid that resulted in a one-
pot preparation of epoxide 40 (scheme 5). At this point, regioselective opening of 
the epoxide with (R)-( + )-sec-phenethyl alcohol in the presence of tetrafluoroboric 
acid-diethyl ether complex gave two diastereomers 41 and 42. 
OH OH 
y~o iv H~OH 
Ph ~ rO ... ~ OH 
0 
(X0H tc}o iii 41 43 i,ii ... ... + ~ OH 
OH OH 27 40 
yo"6"0)=0 iv Ho"6 .. 0H ... 
Ph ~ "'''0 ~ "'''OH 
42 44 
Reagents and conditions: i) (MeOhCO, MeO-Na+, MeOH; ii) mCPBA, CH2C}z; iii) (R)-( + )-sec-phenethyl 
alcohol, HBF4-0Et2, CH2Ch; iv) Na/NH3, Et20, -78°C. 
Scheme 5. Enantiodivergent synthesis of (+)- and (-)-conduritol F. 
After their separation the benzyl ethers were reduced under dissolving metal 
conditions to cleanly cleave the carbonate and the benzyl ether to furnish (+)- and 
(-)-conduritol F 43 and 44. 
Hudlicky has exploited the cis-cyclohexadienediols as a chiral synthon for the 
synthesis of numerous natural protducts including the synthesis of several of the 
13 
Amaryllidaceae alkaloids22-25 especially the first asymmetric total synthesis of (+)-
pacratistatin 52 from (lS-cis)-3-bromo-3,S,-cyclohexadiene-l,2-diol 45.26• 
Acetonide protection of the diol moiety followed by aziridination procedure 
described by Evans27 and finally tri-n-butyltin hydride reduction of the vinyl 
bromoide gave the tosyl aziridine 46 (Scheme 8). Amide 47 was subjected to ortho 
metalation followed by treatment with copper(I) cyanide formed the lithium 
cyanocuprate species which selectively opened the aziridine 46. 
14 
Br 
)-yOH 
U OH 
i-iii ... ~ X+< '.& rxo OJ?-i, 0 0 CONMe2 
45 
51 ! xiii,xiv 
OH 0 
52 
TsN OTBS 
46 47 
x-xii <0 liliiii 
o 
OBn 
50 
iv 
liliiii vii-ix <0 
o 
48 
= 
NHBoc 
CONMe2 
OTBS 
49 
Reagents and conditions: i) DMP, p-TsOH, CH2Clz; ii) PHI=NTs, Cu(acac)2, CH3CN; iii) nBu3SnH, AIBN, 
THF, PhMe, reflux; iv) a) s-BuLi, TMEDA, THF, -90°C; b) CuCN, -90°C to -20 °C; c) BF3-OEt2, -78°C-
RT; v) a) s-BuLi, THF, b) (BochO; vi) Najantharacene, DME, -78°C; vii) TBAF, THF 0 °C; viii) SMEAH, 
THF, morpholine, -45°C; ix) BnBr, KZC03, DMF; x) a) NaCI02, KH2P04, 2-methyl-2-butene, t-BuOH, 
HzO; b) CH2N2, Et20; xi) AcOH, THF, H20, 60°C; xii) t-BuOOH, VO(acac)2' PhH, 60°C; xiii) H20, BzO-
Na+ (cat.), 100°C; xiv) Pd(OH)2jC, Hz, EtOAc. 
Scheme 8. First enantioselective synthesis of (+ )-pancratistatin 52. 
Treating the sulfonamide 48 with s-butyl lithium followed by Boc anhydride 
allowed for the removal of the tosyl group by dissolving metal reduction resulting in 
the carbamate 49. The sHyl ether was cleaved using tetrabutylammonium fluoride 
15 
and the dimethyl amide was then reduced to the aldehyde using sodium 
bis(methoxyethoxy)aluminium hydride. The phenol was then protected as the 
benzoyl ether to provided aldehyde 50. Oxidation of the aldehyde followed by 
treatment with diazomethane afforded the methyl ester. Hydrolysis of the 
acetonide and subsequent treatment with VO(acach and di-tert-butyl peroxide 
(directed by the free hydoxyl groups) formed the epoxide 51. To conclude the 
synthesis the epoxide was treated with aqueous sodium bicarbonate at 100°C 
which stereoselectively opened the epoxide, thermally cleaved the carbamate and 
cyclized the 6-lactam followed by hydrogenation to remove the benzoyl ether 
provided (+ )-pancratistatin 52. 
Banwell utilized the cis-cyclohexadienediol 21 derived from toluene in his 
synthesis of the sesquiterpenoids (-)-hirsutene 6028 and (+ )-histuric acid.29 
Banwell's synthesis of (-)-hirsutene 60 started with a high pressure Diels-Alder 
cycloaddition between cis-cycloxhexadienediol 21 and 2-cyclopenten-l-one 53 to 
form the syn-addition product in 70% yield and anti-product in only 9% yield 
(Scheme 6). 
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Reagents and conditions: i) 19 kbar (70%); ii) DMP, p-TsOH, H20 (90%); iii) LiHMDS, Mel, THF 
(quant.); iv) LiALH4, THF, 0 °C - 50°C (99%); v) NaH, CS2, Mel, THF; vi) nBU3SnH, AIBN, PhMe, reflux 
(50-57% over two steps); vii) AcOH, THF, H20, 60°C (95%); viii) 4-NAc-TEMPO, p-TsOH, CH2Ch, 0 °C 
(91 %); ix) iPr2NEt, MEMCI, CH2Ch (91 %); x) hv (triplet), acetone (80%); xi) nBU3SnH, AIBN, PhH 
(87%); xii) NaBH4, MeOH; xiii) NaH, CS2, Mel, THF; xiv) nBU3SnH, AIBN, PhMe, reflux (83% over three 
steps); xv) PPTS, tBuOH, reflux (76%); xvi) PCC, CH2Ch (71%); xvii) CH3P+Ph3Br, KHMDS, PhMe 
(quant.). 
Scheme 6. Banwell's synthesis of the sequiterepene (-)-hirsutene 60. 
The cycloaddition adducts were separated by column chromatography and the 
resulting diol was protected as the acetonide. To install the gem-methyl groups the 
acetonide was subjected to KHMDS followed by a methyl iodide to give ketone 55. 
Lithium aluminum hydride reduction of ketone 55 gave two epimeric alcohols, 
which were converted to the corresponding xanthates. Allowing for a Barton-
McCombie deoxygenation sequence followed by acid hydrolysis of the acetonide to 
give diol 56. Selective oxidation of the less hindered hydroxy group using the 4-
acetamido-TEMPO and protection of the remaining alcohol afforded keonte 57. 
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Subjecting ketone 57 to a triplet sensitized photolysis resulted in the desired oxa-di-
Jt-methane rearrangement product 58. Triquinane 59 was produced by reductive 
cleavage of the carbonyl-cyclopropyl group with tri-n-butlytin hydride. The ketone 
was reduced using sodium borohydride and deoxygenated using the same Barton-
McCombi deoxygenation sequence. Deprotection of the j3-methoxyethoxymethyl 
ether under acidic conditions followed by a PCC oxidation and finally a wittig 
reaction produced (-)-hirsutene 60. 
Boyd's application of cis-cyclohexadienediol has developed several routes to 
various pyranose carbasugars.30 Two of which are carba-j3-D-altropyranose 66 and 
carba-a-L-galactopyranose 67 dervied from iodobenzene metabolite 61 (Scheme 7). 
Reagents and conditions: i) DMP, p-TsOH (98%); ii) Os04, NMO, acetone, H20 (87%); iii) Pd(OAc)z, CO 
(1 atm), NaOAc, MeOH (81%); iv) Rh/Ah03, H2 (55 psi), EtOH; v) BzCI, pyridine (6428% over two 
steps; 65 56% over two steps); vi) LiAlH4, THF, reflux; vii) TFA (66 67% over two steps; 67 68% 
over two steps). 
Scheme 7. Boyd's synthesis of carbasugars carba-j3-D-altropyranose 66 and carba-
a-L-galactopyranose 67. 
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Protection of 61 as the acetonide allowed for the facially directed dihydroxylation 
I 
using osmium tetraoxide to give vinyl iodide 62. Conversion of the acetonide to the 
a,j3 unsaturated ester 63 was accomplished by palladium catalyzed carbonylation in 
the presence of methoxide. Catalytic hydrogenation of the unsaturated ester gave a 
mixture of diastereomers. This mixture of diastereomers was inseparable therefore 
they were converted to the benzoate ester 64 and 65 to allow for separation by 
preparative layer chromatography. For both series the same sequence of reducing 
all three esters with lithium aluminum hydride and acid catalyzed acetonide 
deprotection afforded the respective carbasugars. 
2.2 Morphine Alkaloids 
2.2.1 History 
Opium has been used by mankind since prehistoric times. It was one of the 
first drugs discovered. The opium poppy (Papaver somniferum) was cultivated in 
the Tigris-Euphrates river system of lower Mesopotamia in 3400 BC by the 
Sumerians, the world's first civilization.31 Researchers from the University of 
Pennsylvania, excavating around the ancient city of Nippur, discovered tablets 
describing the collection of poppy juice from plants they called "Gil Hul" translating 
as "joy plant".32 The collection of secretions from the opium poppy was also 
performed by the Assyrainas who named the juice collected "arat-pa-pal". Which 
some have speculated that the latin word "Papver" (botanical genus of the opium 
poppy) is derived from this term.33 The spread of opium out of Mesopotamia was 
sparked by the conquest of the Assyria and Babylonia by the Persians around the 
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sixth century BC. One of the oldest known medical texts, the Ebers Papyrus dating 
back to 1552 BC, contains the 700 remedies, which include opium in their 
treatment.34 
Between the 11th and the 13th centuries, medical uses ofthe opium poppy was 
introduced to the Chinese by the Arab traders.33 However, opium was used chiefly 
by the elite until the introduction of smoking tobacco by European sailors in the 15th 
century. When the Ming emperor, Tsung Cen, banned the use of tobacco the Chinese 
people responded by mixing opium with tobacco for smoking in special pipes. By 
the end of the century approximately 25 percent of the population was smoking 
pure opium and thus historically opium use became synonymous with China.34 
In the 18th century, the British Empire had a growing trade deficits with China. 
Thus the British Empire and the British East India Company responded by supplying 
opium to China to avoided bankruptcy. The Chinese responded by prohibiting the 
sales and use of opium. After the ban, British smugglers increased opium exports 
from 15 tons to 75 tons in less than 45 years.35 The continued illegal import of 
opium caused tensions between the east and west which resulted in two conflicts 
known as the Opium Wars. Despite China losing in both conflicts the opium trade 
waned because of an anti-opium movement, as well as the British Empire became 
less dependent on the revenue from the sales of opium.34 Because of this trade 
opium spread around the world but at the end of the 19th century the use of raw 
opium was reduced, as the active components of opium were isolated. The use of 
raw opium still continues today around the world, but not to the extent of purified 
and extracted alkaloids from opium.36 
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Opium is the air-dried exudate collected from lancing the unripen seed pods of 
Papaver somniferum.33 The collected residue contains approximately 10-15% 
morphine 68, 3-4% codeine 70,1-7% narcotine 72, 0.5-1% papaverine 71 and 0.1-
2% thebaine 70 as shown in figure 7.37 
HO 
HO"'" 
morphine 68 thebaine 69 
MeO 
papaverin 71 
Figure 7. Naturally occurring opium alkaloids. 
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narcotine 72 
MeO 
HO"'" 
codeine 70 
In 1806, pharamacist Friedrich Wilhelm Sertiirner isolated the alkaloid 
morphine 68 from raw opium.38-39 Sertiirner coined the name "morphine" after 
Greek god Morpheus, God of Dreams. Shortly after the isolation of morphine, the 
structural elucidation began and early studies by Liebig and Laurent, in 1847, 
correctly determined the empirical formula as C17H19N03.40 Wright is credited with 
the most important work in the elucidation of morphine's oxygenation.41-42 This 
was followed by the establishment of the oxygenated phenanthrene core by 
degradation studies completed by Greichten, Hofmann, and Pschorr.43-47 In 1952, 
the correct structure of morphine was proposed by Robinson48 and confirmed by 
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the first total synthesis by Gates in 1952.49 The absolute configuration of morphine 
was completed by MacKay and Hodgkin with the advent of X-ray diffraction 
analysis. 50 The complete story of isolation, structure elucidation and synthesis of 
morphine spans more than 150 years and is the subject of s,everal reviews.51-52 
These accomplishments defined the early beginnings of modern organic chemistry 
and should be viewed as standards of sound thought and science. 
2.2.2 Biosynthesis of morphine alkaloids 
,The biosynthesis of morphine and congeners have been elucidated as shown in 
figure 8.53-54 All of the carbon atoms of morphine core come from two L-tyrosine 73 
molecules which have "dimerised". In the first stage of biosyntheis, one molecule of 
tyrosine is converted into dopamine 74 by two enzymes, a tyrosine decarboxylase 
and a phenol oxidase. The second molecule of tyrosine 73 is converted to p-
hyrdoxyphenylacetaldehyde 75 by the action of a transaminase followed by the 
decarboxylation. 
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Figure 8. Biosynthesis of morphine. 
These two pieces are coupled together by (SJ-norcodaurine synthase via a Pictet-
Spengler type reaction to form (SJ-norcodaurine 76. Oxidation followed by 
methylation give (SJ-reticuline 77, which is then epimerized by an oxidation 
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reduction sequence by 1,2-dehydroreticulinium reductase to give (R)-reticuline 
78.55 An oxidative phenol coupling catalyzed by a microsomal NADPH-dependent 
cytochrome P450 couples carbon 12 to carbon 13 (morphine numbering) to give 
salutaridine 80, which establishes stereospecifically the quaternary center of the 
morphine skeleton. Salutaridine 80 is then reduced to form salutaridinol 81 and 
thenacetylated by salutaridinol 7 -O-acetyltransferase. The phenolic hydroxyl 
displaces the allylic acetate by SN2' reaction yielding thebaine 69. Thebaine is 
demethylated to form neopinone 1 by a recently discovered enzyeme thebaine 6-0-
demethylase.56 Neopinone 1 which exists in an equilibrium with codeinone 82 is 
then reduced by codeinone reductase resulting in codeine 70 which in turn is 
demethylated by codeine-O-demethylase to morphine 68.37,57 
The biosynthetic pathway of the production of morphine is considered to be 
well understood.54 However the existence of thebaine oripavine poppy 1 (topl) 
mutant poppy which produces oripavine and thebaine 69 and not morphine 68 and 
codeine 70 suggest the presence of an alternative biosynthetic pathway for the 
conversion of theabine 69 to morphine 68.58 It was proposed the mutation of the 
enzyme responsible for demethylation of the C-6 oxygen of thebaine 69 in the 
poppy mutant top1 is responsible for the break in the morphine biosynthetic 
pathway and thus explains the accumulation of oripavine and thebaine 69.59 
2.2.3 Pharmacology 
Opioids constitute one of the oldest drugs known to man and are among the 
most effective treatments available for pain relief.60 Morphine 68 and other 
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congeners have major effects on the central nervous system which are responsible 
lowering the brain's awareness of pain. However, these benefits can be outweighed 
by the side effects of opioids; which include, but are not limited to, respiratory 
suppression, constipation, convulsions, hallucinations and physical dependence.61 
In 1954, Beckett and Casy attempted to explain the effects of opiods on the 
central nervous system.62 They proposed that morphine and its congeners required 
specific binding interactions for their activity. These included a positively charged 
nitrogen, correctly orientated aromatic ring, a C-3 phenol and a binding pocket to 
allow for the ethylene bridge. By the late 1960s, Goldstein postulated that the 
different activities of opioid agonists, antagonists and mixed agonists-antagonists 
were a result of multiple opiate receptors. At the time their labors to prove this 
theory failed because of the poor availability of radiolabeled opiates.63 However, in 
1973 three groups simultaneously proved Goldstein's hypothesis by indentifying 
multiple opioid receptors.64-66 Questions arose whether morphine was not an 
endogenous opioid ligand. This was confirmed by the work of Kosterlitz in 1975, 
who showed mammalian brain extracts contained substances that inhibit the 
acetylcholine release from nerves.67 The agents responsible for this act were 
identified as met-enkephalin 86 (Tyr-Gly-Gly-Phe-Met) and Leu-enkephalin 87 
(Tyr-Gly-Gly-Phe-Leu)68 (figure 9). Other peptidic endogenous opiod receptor 
ligands were identified varying in length from 5 to 33 amino acids and are known as 
endorphins (endogenous morphine). 60 
Spread throughout the central nervous system is the presences of opioid 
receptors. There are three commonly recognized opioid receptors: Il, K and ~ 
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receptors, all of which exhibit analgesic properties but to various levels. All of these 
receptors show structural homology with each other; however, they act through 
different modes of action.69 
Agonist activation of the Il-recpetor results in analgesia as well as side effects 
of euphoria, respiratory depression, constipation and addiction. Opioid binding to 
the Il-receptor induces a conformational change that opens an ion channel. This 
allows the potassium ions to flow out of the cell resulting in an increase of 
membrane polarization. This results in a decrease in the influx of calcium ions 
causing synaptic inhibition.33 Endogenous ligands include enkephalins and (3-
endorphins, while morphine is a standard of an exogeneous opiod. Opioid abuse can 
be treated with naloxone 84 and naltrexone 83, both of which are antagonists of the 
Il-receptor. 
Activation of K-receptor is directly associated with calcium channels. Binding 
closes the calcium channel and therefore prevents the release of neurotransmitters, 
as calcium is required for this to occur. The kappa receptors are related to non-
thermal pain stimuli where as with the wreceptor all pain messages are inhibited.70 
It is interesting to note that K-agonists do not show the addictive and physical 
dependence as that of wagonists and thus could show promise of a "safe" 
analgesic.69 However clinical trials of K-agonists have shown dysphoric and 
psychotomimetic effects.71 
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naltrexone 83 naloxone 84 
Met-enkephalin 86, R= methionine 
Leu-enkephalin 87, R= leucine 
7 -spiroindanyloxymorphone 86 
morphine 68 
Figure 9. Selective opioid receptor agonists and antagonists. 
The a-receptor is a G-protein linked receptor. When an agonist binds the 
protein under goes a conformation change resulting in the fragmentation of the 
messenger Gi-protein. This fragmentation inhibits the membrane bound adenylate 
cyclase from produce cAMP. cAMP is required for the transmission of pain singals 
and therefore stops the signa1.6o Endogenous agonist of a-receptors are Met and Leu 
enkephalins 86 and 87 and an excellent example of an exogenous agonist is 7-
spiroindanyloxymorphone 86.72 
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2.2.4 Selected Syntheses73 
Morphine and its congeners have attracted the attention of chemists for well 
over 200 years. Since the first synthesis of morphine by Gates and Tschudi in 1952 
the interest in morphine as a synthetic target has not waned.!. 57. 74-75 Despite 
morphine's small size, it is complex target because of the pentacyclic framework, 
five contiguous stereocenters, the C-4 C-5 ether bridge. Of considerable challenge is 
the completely dissonant, incorrect polarity assignment of an electronegative atom 
or two adjacent like charges, assemblely of the 17 carbons of morphine (figure 10),1 
The following sections highlights a selection of the efforts towards the total 
synthesis of morphine alkaloids to date. 
morphine 68 
Figure 10. Dissonant relationship in morphine connectivity 
Gates (1952)49.76 
In 1952, Gates and Tschudi published the first total synthesis of morphine as a 
two-page communication, confirming Robinson's proposed structure.49 The full 
disclosure of the synthesis appeared four years later,76 Their synthesis required 24 
steps to construct morphine 68 from 2,6-dihydroxynapthalene 88 in an overall yield 
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of 0.01 %. The synthesis begins with the conversion of 2,6-dihydroxynapthalene 88 
by a nitrosation/ reduction/ oxidation sequence into the quinone 89 (scheme 10). 
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Reagents and conditions: (i) BzCI, pyridine, dioxane; (ii) NaNOz, AcOH; (iii) a) Pd/C, Hz, AcOH; b)FeCh; 
(iv) a) SOz; b) (MeO)2S0z/KzC03; (v) KOH; (vi) NaN02, AcOH; (vii) a) Pd/C, Hz; b)FeCh; (viii) a) 
NCCHzCOzEt, EtOH, NEt3; b)K3Fe(CN)6; (ix) KOH, MeOH; (x) 1,3-buatdiene, AcOH. 
Scheme 9. Gates' synthesis of the Diels-Alder product 93 
This allowed for the installation of two unique 1,2-dioxygen functionalities on both 
rings. Michael type addition of ethyl cyanoacetate to 91 followed by a oxidation 
decarboxylation sequence resulted in nitrile 92. The installation of the e-ring was 
performed by a Diels-Alder reaction with 1,3-butadiene giving 93. By performing 
reductive cyclization using copper chromite under "mild conditions" (130 °e, 27 atm 
of hydrogen), as reported by the authors, the O-ring was closed to form the keto 
amide (scheme 10). 
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Reagents and conditions: (i) 27 atm H2, CuO, Cr203, EtOH, 130De (50%); ii) KOH, N2H4 (90%); iii) a) 
NaH, Mel; b) LiAlH4 (54%); iv) H2S04, H20 (28%); v) KOH, ethylene glycol (54%); vi) KOtBu, Ph2CO 
(89%); vii) Br2, AcOH, 2,4-DNPH (41%); viii) HCI; ix) H2, Pt02; x) Br2, AcOH, 2,4-DNPH (26%); xi) HCI, 
acetone (27%); xii) LiAIH4 (quant.); xiii) Py·HCI, 220D C (35%). 
Scheme 10. Gate's final transformations to morphine 68. 
Gates states the course of the reductive cyclization leading to the tetra cyclic 
skeleton "was far from clear". Wolff-Kishner reduction of the ketoamine followed by 
methylation and reduction with LAH afforded N-methyl piperidine 94 containing all 
the necessary carbons of morphine. A resolution of 94 was performed by 
crystallizations with D-dinitrobenzoyltartaric acid. Unfortunately this provided the 
correct stereochemistry at C-9 and C-13 but the epimer at C-14. Hydration of C-6 
was performed using dilute sulfuric acid. Selective demethylation of the proximal 
methyl ether followed by oxidation furnished ketone 96. To resolve the 
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stereochemistry at C-14, compound 96 was treated with two equivalents of bromine 
followed by the hydrazone formation with 2,4-DNPH as shown in figure 11. This 
introduced an a,p-unsaturation, as seen in compound 100, which allowed for the 
equilibrium of the hydrogen at C-14 to the more stable cis fused ring system 102. 
Acid meditated hydrolysis followed by hydrogenation to reduce the a,p-
unsaturation formed by the introduction of the hydrazone gave ketone 97 with the 
correct stereochemistry at C-14. Closure of the E-ring was accomplished by 
bromination of 97 followed by treatment with 2,4-DNPH and installed the a,(3-
unsaturation. Gates finished his synthesis with hydrolysis of the hydrazone 
followed by reduction to give codeine 70. Follwing Rappoport's conditions for the 
demethylation of codeine completed the first synthesis of morphine 68.77 
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Figure 11. Epimerization of C-14. 
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Rice (1980)18 
The formal syntheis of morphine 68, completed by Rice in 1980, is arguably 
the most practical synthesis to date. The biomimetic approach allows for the 
synthesis of both the natural and unnatural enantiomers of hydrocodone 109. The 
synthesis was completed with only six intermediates, no chromatography and the 
overall yield is an astounding 29%. 
The synthesis begins with the condensation of amine 103 and acid 104 
followed by a Bischler-Napieralski reaction and treament of the resulting imine with 
sodium cyanoborohydride gave the cyclized amine 105 (scheme 11). Birch 
reduction followed by formylation with phenyl formate furnished 106. Protection 
of the masked ketone with ethylene glycol and regioselective bromination gave the 
cyclization precursor 107. Acidic hydrolysis of the ketal followed by a hydrogen 
fluoride mediated Grewe cyclization provided the tetracyclic core of morphine in 
60%. Mild hydrolysis of the formamide 108 followed by a-bromination of the 
ketone initiated the E-ring closure. Hydrogenation in a mixture of acetic acid and 
formaldehyde removed the aryl bromide and methylated the secondary amine 
providing hydorcodone 109, a formal synthesis of morphine 68. 
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hydrocodone 109 
Reagents and conditions: i) 200°C (95%); ii) POCh, MeCN; iii) NaCNBH4, MeOH (86%); iv) Li, NH3, 
THF, tert-BuOH (90%); v) PhOCHO, EtOH (94%); vi) ethylene glycol, MES03H, THF; vii) NBA (88%); 
viii) HC02H-H20 (90%); ix) NH48 HF, CF3S03H (60%); x) MeOH, HCI (92%); xi) H2, PdjC,AcOH, HCHO; 
xii) Br2, AcOH; xiii) NaOH, CHCh; xiv) H2, AcOH, HCHO (79% over 4 steps) 
Scheme 11. Rice's synthesis of hydro cod one 109. 
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Overman (1993)79 
Overman's synthesis of morphine was the first published enantiodivergent 
approach to morphine that did not involve resolution of intermediates. The key step 
to overman's synthesis was the use of iminium ion-allylsilane cyclization followed 
by an intramolecular Heck reaction. The synthesis starts with the preparation of the 
A-ring from isovanilin 110 with the protection of the phenol and the aldehyde to 
give the ketal 111 (Scheme 12). 
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Reagents and conditions: i) HC(OMe)3, HCl; ii) NaH, CICH20Me; iii) n-BuLi, Iz (80%); iv) 6N HCl; v) 
BnBr, K2C03 (97%); vi) CH2SMe2 (91%); vii) BF38 0Et2, THF (92%); viii) 115, catechol borane (93%); 
ix) PhNCO (93%); x) OS04, acetone, HCI (78%); xi) a) n-BuLi, THF, -30°C; b) CuI (PPh3)z, O°C; c) 
PhMe2SiLi, O°C (81%); xii) p-TsOH, MeOH, NaI04; xiii) DBS-NH2, NaCNBH3 (88%). 
Scheme 12. Overman's preparation of morphine precursors 113 and 119. 
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Lithiation of compound 111 followed by quenching with iodine, and acidic 
hydrolysis and reprotection as the benzyl ether afforded aldehyde 112. Treatment 
of the aldehyde with dimethylsulfonium methylide followed by Lewis catalyzed 
rearrangement of the resulting epoxide provided the desired aldehyde 113. 
The coupling partner was prepared from 2-allylcyclohex-2-enone 114 by 
enantioselective reduction with catecholborane in the presence of a chiral catalyst, 
(R)-oxazaborolidine 115, to yield (SJ-cyclohexenoI116 in 96% ee. Condensation of 
the alcohol with phenyl isocyanate followed by selective catalytic dihydroxylation of 
the terminal olefin and protection provided the acetonide 117. Treatment of 
compound 117 with n-butyllithium, CuI(PPH3)2 and PhMe2SiLi allowed for the [3,3] 
sigmatropic rearrangement followed by the SN2' displacement of the allylic 
carbamate resulting in the formation of the allylsilane 118. Hydrolysis of the 
acetonide followed by periodate cleavage of the diol resulted in the desired 
aldehyde. Which upon treatment with dibenzosurberylamine followed by reduction 
with sodiumborohydride gave coupling precursor 119. 
Condensation of the aldehyde 113 with the amine 119 in the presence of 
zinc(II) iodide followed by the aforementioned iminium ion-allylsilane cyclization 
provided the desired octahydroiosquinoline 121 (scheme 13). The preferential 
approach of the (E)-iminium ion intermediate 120 from the face opposite to that of 
the allylsilane results in the high diastereoselectivity of 20:1. 
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Reagents and conditions: i) Znh, EtOH, 60°C (82%); ii) Pd(TFA)z(PPh3)z, 1,2,2,6,6-
pentamethylpiperidine, toluene (60%); iii)BF3·0Etz, EtSH (79%); iii) CSA, 3,5-dinitroperoxybenzoic 
acid (60%); iv) TPAP, NMO (86%); v) Hz, Pd(OH)z, HCHO (80%). 
Scheme 13. Overman's formal synthesis of hydro cod one 109. 
Sequential Heck cyclization resulted in the unsaturated compound 122. 
Deprotection of the benzyl ether followed by treatment with camphorsulfonic acid 
and 3,5-dinitroperoxybenzoic acid allowed for the closure of the ether bridge 
between C-4 and C-5. The formal synthesis of morphine was concluded by oxidation 
of the alcohol 123 and hydrogenation of the DBS group providing hydrocodone 109. 
Fukuyama (2006)80 
In 2006, Fukuyama disclosed his synthesis of rae-morphine. The approach 
featured a Tsuji-Trost coupling81-82 followed by a Heck coupling, which was 
employed in Trost's synthesis of morphine83-84, furnished the tricyclic core of 
morphine. The closure of the penatcyclic ring systems was finished by a Mannich-
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type reaction as seen in Figure 12. The synthesis was performed using a racemic 
epoxide, however generation of a chiral epoxide 128 could furnish access to the 
natural and unnatural series of morphine. 
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Figure 12. Fukuyama's strategy for the synthesis of morphine 68.80 
Similar to that of Overman's synthesis, Fukuyama's starts with the conversion 
isovanillin 110 to the aryl iodide 130 by protection of the phenol and aldehyde 
followed by iodination (Scheme 14). Acidic hydrolysis of the acetal and subsequent 
olefin elongation via Wittig reaction furnished the homoisovanilin. Deprotection of 
the phenol via hydrolysis in methanol provided the A-ring coupling partner 131. 
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0" C02H 6~S vi-viii ((" ix-xi .. .. '7 .., ~ Br .".0 
132 133 134 
Reagents and conditions: i) MOMCI, iPrzNEt; ii) CSA, HC(OMe)3; iii) n-BuLi, Iz (72% over 3 steps); iv) 
AcOH, THF, H20 (89%); v) MeOCHzPPh3CI, NaHMDS, THF (95%); vi) HCI, MeOH, 40°C (96%); vi) Na, 
NH3, EtOH, -78°C; vii) a) AcC!, MeOH; b) NaOMe; viii) NBS, H20, DMSO (62% over 3 steps); ix) DIBAL, 
CHzC}z, 0 °C (73%); x) NaOMe, MeOH; xi) TBSCI, imidazole, CH2Clz (61% over two steps). 
Scheme 14. Preparation of coupling partners 131 and 134. 
Synthesis of the epoxide 134, which was previously reported by Fukuyama in his 
synthesis of strychnine,85 started with the Birch reduction of benzoic acid 132 
followed by isomerization of the double bond and treatment with N-
bromosuccinimide to form the bromohydrin 133. Reduction of the ester and 
treatment under basic conditions afforded the desired epoxide. Protection of the 
alcohol as the sHyl ether furnished the desired coupling partner 134. A palladium 
mediated Tsuji-Trost coupling afforded the ether 135 (scheme 15). Inversion of the 
allylic alcohol was performed with p-nitrobenzoic acid under Mitsunobu conditions 
followed by deprotection of the silyl ether and a second Mitsunobu reaction using 2-
hydroxy-2-methylpropanenitrHe gave the desired nitrile 136. Hydrolysis of the 
ester and protection as the sHyl ether was performed prior to reduction of the 
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nitrile. To avoid reductive cleavage of the aryl iodide the nitrile was treated with 
diisobutylaluminium hydride followed by the addition of sodium hydride in MeOH 
to furnish the amine, which was then protected with methyl chloroformate to 
furnish the amide 137. With amide 137 in hand, the crucial intramolecular Heck 
cyclization was performed to give the silyl enol ether, which was deprotected in one 
pot to provide the ketone 138. To finish the pentacyclic core system of morphine, 
Fukuyama heated ketal 138 with methanolic hydrogen chloride which proceeded 
smoothly through a Mannich-type reaction to close the C9-C-14 bond. Ketone 137 
was converted to the enone via conversion to the sHyl enol ether followed by 
treatment with palladium(II) acetate, conditions reported by Ito and Saegusa86. This 
enone was then oxidized to the corresponding epoxide 140 with hydrogen peroxide. 
Reduction of the ketone with sodium borohydride resulted in the alcohol, which was 
converted to the thiocarbamate. Treatment with tributyltin hydride induced the 
opening of the epoxide and Barton-McCombie dexoygenation to provide the allylic 
alcohol. To obtain the correct chemistry at C-6 a two step oxidation/reduction 
sequence where the carbamate was also reduced to the tertiary amine giving 
codeine 70. Following Rice's procedure for O-demythlation using boron tribromide 
furnished morphine 68.87 
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Reagents and conditions: i) Pd2(dbah, P(2-furylh, MeCN (91%); ii) p-nitrobenzoic acid, DEAD, PPh3, 
toluene, 0 °C (90%); iii) CSA, MeOH (94%); iv) 2-hydroxy-2-methylpropanenitrile, DEAD, PPh3, 
toluene, 0 °C v) LiBH4, Et20, MeOH, 0 °C (95% over 2 steps); vi) TBSCI, imidazole (96%); vii) a) 
DIABLH, CH2C}z -78°C; b) NaBH4, MeOH, -78°C; c) CIC02Me, K2C03 (94%); viii) a) Pd2(dba)3, P(o-
tolylh, NEt3, MeCN; b) TBAF (87%); ix) HCI, MeOH, reflux (94%); x) TMSCI, LiHMDS, THF, 0 °C xi) 
Pd(OAc)2, MeCN (92% over two steps) xii) H202, H20, NaOH, MeCN, 0 °C (91%); xiii) NaBH4, MeOH, 
CH2C}z,0 °C (91%); xiv) TCDI, DMAP, CICH2CH2CI, 60°C; xv) Et3B, n-Bu3SNH, THF (48% over two 
steps); xvi) Dess-Martin periodinanel, CH2Clz (96%); xvii) LiAlH4, THF (81%); xviii) BBr3, CH2Clz 
(74%). 
Scheme 15. Conclusion of Fukuyama's synthesis of morphine. 
40 
Hudlicky (1996 to present) 
The Hudlicky group presented numerous approaches to morphine based on a 
wide range of unique strategies over the last 20 years. The common feature amoung 
these approaches have been the use of cis-cyclohexadienediols generated by 
enzymatic transformations of arenes. A brief review of Hudlicky's labors in the 
practical synthesis of morphine and its congeners will be presented in the following 
pages. 
Radical cydization approacb51-52, 74, 88-90 
Inspired by the work of Parker,91-92 Hudlicky designed several radical 
cyclization approaches to morphine alkaloids. All of the approaches utilized the 
enzymatic cis-dihydroxylation of arenes as the source of chiral building blocks. 
Hudlicky's first approach started with the 1,2-diol metabolite of o-bromo-j3-
bromoethylbenzene 142 (scheme 16). Diimide reduction of the distal olefin using 
potassium azodicarboxylate under acidic conditions gave dio1143. Protection of the 
diols with ethylene glycol afforded the acetonide, which was followed by the 
subsitution of the alkyl bromide with oxazol-2(3H)-one produced the radical 
cyclization precursor 144. Treatment of compound 144 with n-tributyltinhydride 
and AIBN followed by treatment with acid Dowex resin furnished a 2:1 mixture of 
octahydroisoquinolines 145 and 146, in the favour of the undersired epi-C9 
configuration. 
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Reagents and conditions: i) E. coli JMI09 (pTDG602) (0.2gjL); ii) PAD, AcOH, MeOH (50%); iii) 2,2-
dimethoxypropane, p-TsOH (90%); iv) 2-oxazolidone, NaH, DMSO (38%); v) n-Bu3SnH, AIBN, 
benzene, reflux (87%); vi) Dowex 50X8-100, MeOH (94%); vii) TBSOT[, i-PrzNEt, CHzC}z (85%) viii) 
147, DEAD, PPh3, THF (94%); ix) n-Bu3SnH, AIBN, benzene, reflux (47%); x) TBAF, THF (quant.) xi) 
DIBAL-H, CHzC}z, 0 °C (87%) xii) (COClh, DMSO, NEt3, CHzClz (66%); xiii) TFA (58%); xiv) MsCI, NEt3, 
THF (87%); xv) AICh, toluene, reflux. 
Scheme 16. Hudlicky's synthesis of ent-morphinans 151 and 153. 
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Protection of the homoallylic alcohol as the sHyl ether followed by a Mitsunobu 
inversion with 2-bromo-6-methoxy phenol installed the A-ring of morphine and 
) 
yielded the precursor for the second radical cyclization. Exposure of compoud 148 
to radical conditions resulted in a single diastereomer 149. Reduction of the 
oxazilidinone 149 with DIBAL-H, desilylation, hydrogenation and Swern oxidation 
furnished the ketoaldehyde 150. Friedle-Crafts cyclization was initiated by 
treatment of the ketoaldehyde with trifluoromethane sulfonic acid closing the D-
ring to give 10-hydroxy-14-epi-hydrocodone 151. If the oxazolidinone was reduced 
to the alcohol and mesylated it would allow for the D-ring to be closed via 
displacement. 
In 1998, Hudlicky disclosed his second radical cyclization approach to 
morphine. His synthesis started with the dioxygenase mediated dihydroxylation of 
p-bromoethylbenzene ·154 (Scheme 17). Diimide reduction and protection of the 
distal alcohol gave the silyl ether 156. 
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Br Br Br o~o 
6 i-ii iii .. :&N~ Ho'6 HO:2, IV-VI .. .. ... BzO -..:::: HO"'" TBSO"'" TBSO'·· 
154 155 156 157 
~~i 
MeO MeO Q-6N~ viii + IIIIIIIIE MeO 0"", -..:::: l::::::t0 
TBSO"'" 
160 159 158 
Reagents and conditions: i) E. coli JM109 (pTDG602) (10gjL); ii) PAD, AcOH, MeOH (80%); iii) 
TBSOTt; i-PrzNEt, CHzClz (47%); iv) PhCOzH, DEAD, n-Bu3P, THF (84%); v) 2-oxazolidone, NaH, 
DMSO (71%); vi) NaOH, HzO; vii) 2-bromo-6-methoxy phenol, DEAD, n-Bu3P, THF (28% over two 
steps); viii) (TMS)3SiH, AIBN, 140°C, sealed tube (15%). 
Scheme 17. Hudlicky's second generation radical cyclization approach. 
Mitsunobu inversion of the allylic hydroxyl with benzoic acid followed by 
displacement of the alkyl bromide with oxazol-2(3H)-one and ester hydrolysis 
allowed for selective deprotection of the allylic alcohol provided the CoRing 
fragment of morphine 157. 
Installation of the A ring was performed by a second Mitsunobu with 2-bromo-
6-methoxy phenol to set the correct stereochemistry at CoS. Exposure of compound 
158 to tris(trimethylsilyl)silane and azobisisobutyronitrile afforded a complex 
mixture of compounds. Column chromatography of the mixture afforded compound 
160 as the predominate diastereomer in a yield of 15%. Trace amounts of a second 
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diastereomer 159 were detected. Hudlicky's previous methods to close the D-ring 
would finish the core of morphine. 
Heck cyclization Approach89-90, 93-95 
The Hudlicky group also explored the use of a Heck cyclization strategy to correct 
the C-14 stereochemistry that the radical cyclizations produced when the C9-C14 
bond was inplace. Similar to the radical cyclization approaches the isoquinoline 
intermediate was used to install the B- and C-rings. Biooxidation of ~­
bromoethylbenzene 154 provided the chiral starting material 6 (Scheme 18). The 
cis-cyclohexadienediol 6 was treated with potassium azodicarboxylate with acid to 
selectively reduce the distal olefin, the hydroxyl groups were esterified and the alkyl 
halide was displaced with oxazoldine-1,4-dione to give the heterocycle 161. 
The more reactive amide carbonyl was reduced with sodium borohydride and then 
treated with aluminum chloride to induce an N-acyliminium ion-olefin cyclization to 
give the iosquinoline 162. Elimination of the alkyl chloride with 1,8-
diazabicyclo[S.4.0]undec-7-ene followed by ester hydrolysis furnished diol 163. 
Selective protection of the homoallylic hydroxyl group with p-toluenesulfonyl 
chloride followed by Mitsunobu inversion of the allylic hydroxyl afforded bis 
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protected trans diol 164. 
Br Br O~~O OH 
6 HO § CI .. HO'6 ii-iv ... 8Z0'6 v-vi 'CQro .. HO"'" .& BzO"'" 
154 6 161 162 
~ vii-viii 
~ro OBz OH xi TSO'~ ix-x HO'~ ... ... N)==O )==0 0 0 
165 164 163 
Reagents and conditions: i) E. coli IM109 (pTDG602) (10gjL); ii) PAD, AcOH, MeOH (80%); iii) 
PhCOzH, DCC, CHzClz (83%); iv) oxazoldine-1,4-dione, tetramethylguanidine, THF (77%); v) NaBH4, 
MeOH, THF (qunat.); vi) AICh, CHzClz (57%, cis:trans = 3.7:1); vii) DBU, DMSO, reflux (25%); vi) 
LiOMe, THF (85%); vii) TsCI, pyridine, DMAP (45%); PhCOzH, PPh3, DEAD, THF (84%); k) NaOMe, 
MeOH, THF (65%). 
Scheme 18. Synthesis of the isoquinoline derivative. 
Basic ester hydrolysis of compound 164 resulted in epoxide 165. Regio- and 
setereoselective opening of the epoxide 165 with the potassium salt of 
bromoguaicol 166 and protection of the resulting hydroxyl as the sHyl ether 
furnished 167 (scheme 19). An intramolecular Heck reaction gave the pentacyclic 
carbamate 168. Reduction and treatment with tetra-n-butylammonium fluoride 
provided alcohol 169. Compound 169 was subjected to hydrogenation with Adam's 
catalyst and Swern oxidation that resulted in the unexpected epimer at C-14. 
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Treatment of the ketoaldehyde 170 with trifluoromethanesulfonic acid finished the 
synthesis of 10-hydroxy-14-epi-hydrocodone 171. 
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Reagents and conditions: i) DME, 18-crown-6 (80%); ii) TBSOTf, iPr2NEt, CH2Clz (74%); iii) Pd(PPh3)4, 
Proton Sponge™, toluene (74%); iv) DIBAL-H, CH2Clz (69%); v) TBAF, THF, H20 (77-86%); vi) Hz, 
Pt02, AcOH (64%); vii) (COCI)2, DMSO, NEt3, CH2Clz; viii) TFA (30% over two steps). 
Scheme 19. Hudlicky's Heck cyclization approach to morphine. 
In Hudlicky's second generation of his Heck cyclization approach, he 
employed two intramolecular Heck cyclizations to construct the C-B-D rings of 
morphine. This approach like the previous utilized the same cis-cyclohexadienediol 
6 as the chiraI precursor (scheme 20). The distal olefin was selectively reduced 
with diimide followed by protection of the hydroxyl to give the diacetate 172. 
Treatment of the diacetate with methylamine gas in a sealed tube and then di-tert-
butyl carbonate resulted in substituion of the alkyl bromide and subsequent 
hydrolysis of the diacetates. Selective protection of the homoallylic hydroxyl as the 
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sHyl ether furnished the C-ring fragment 173. Mitsunobu inversion with 
bromoisovanillin 174 gave the aryl bromide 175 and the first Heck reaction closed 
the E-ring. 
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Reagents and conditions: i) E. coli JM109 (pTDG602) (10gjL); ii) PAD, AcOH, MeOH (80%); iii) AczO, 
NEt3, DMAP, CHzClz (79%); iv) a) MeN Hz, K2C03, THF, -40 DC to ODC; b) (BochO, NEt3, MeOH (50%); v) 
TBSCI, imidazole, CH2Clz (88%); vi) n-Bu3P, DIAD, THF, ODC (55%); vii) Pd(OAc)z, AgZC03, dppf, 
toluene, 110DC (82%); viii) PPh3CHzBrz, t-BuOK, THF -60DC (49%); ix) Pd(OAc)z, AgZC03, dppp, 
toluene, 110DC (44%); x) TBAF, THF; xi) IBX, DMF; xii) NaBH4, CeCb e 7HzO, MeOH, ODC (72% over 
three steps); xiii) TFA, CH2Clz (88%); xiv) a) Hg(OAc)2' NEt3; b) LiALH4 (18%). 
Scheme 20. Hudlicky' Synthesis of ent-codeine. 
A Wittig reaction on aldehyde 176 provided the vinyl bromide 177. The second 
Heck precursor 177 was subjected to the second Heck reaction completing the 
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phenanthrene core. Deprotection of the silyl ether 178 followed by oxidation/ 
reduction sequence was performed to set the correct stereochemistry at C-6 
furnishing allylic alcohol 179. Carbamate hydrolysis gave the enantiomer to Trost's 
intermediate.83 Attempts to repeat Trost's conditions were unsuccessful. Therefore 
the olefin was subjected to oxymercuration that was quenched with the ethylamino 
bridge. Subsequent lithium aluminum hydride reduction completed the synthesis of 
ent-codeine 70. 
Utilizing the aforementioned approach, Hudlicky published his 
enantiodivergent synthesis of (+)- and (-)-codeine in 2009. This synthesis started 
with the same diol 6 as his 2007 publication. Selective reduction of the distal olefin 
with potassium azodicarboxylate, protection of the hydroxyls as the diacetates 
yielded 172. Subjecting diacetate 172 to methylamine gas in a sealed tube and 
subsequent protection with tert-butyl carbamate provided diol180 (scheme 21). 
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Reagents and conditions: i) E. coli JM109 (pTDG602) (10gjL); ii) PAD, AcOH, MeOH (80%); iii) AczO, 
NEt3, DMAP, CHzCh (79%); iv) a) MeNHz, KZC03, THF, -40°C to O°C; b) (Boc)zO, NEt3, MeOH (50%); v) 
p-NOzC6H4COzH, DIAD, PPh3, THF (71%); v) TsCI, NEt3, DMAP, CHzCh (73%); vi) NaOMe, MeOH, THF 
(88%); vii) 5, 18-crown-6, DME-DMF (75%); viii) TBSCI, imidazole, CHzCh (61 %). 
Scheme 21. H udlicky' s synthesis of of (-) -codeine. 
Following a procedure developed by Banwell,28 the allylic alcohol was inverted with 
p-nitrobenzoic acid via Mitsunobu inverion. Protection of the homoallylic hydroxyl 
with p-toluenesulfonyl chloride gave the tosylate 181. Basic ester hydrolysis 
allowed for the displacement of the tosylate furnished the epoxide 183. Selective 
opening of the epoxide with the potassium salt of bromoisovanillin 182 and 
subsequent silyl protection gave the enantiomer 184. This can be converted 
following Hudlicky's previously reported protocols to give the natural isomer of 
codeine 70. 
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3. Discussion 
3.1 Introduction 
Morphine, codeine and other semi-synthetic opiods are among the most 
commonly used pharmaceuticals. The consumption of morphine in North America 
for 2011 is estimated to be approximately 106 tonnes31. The supply of opium 
alkaloids depends solely on the isolation from the opium poppy. Which can only be 
harvested from opium plants grown in a few specific regions, including Iran, 
Afghanistan, Turkey and India. Many of these countries are under political turmoil, 
making the supply of opiates questionable. In order to relieve the Western world's 
reliance on these countries a practical synthesis that rivals that of isolation from the 
opium poppy is required. Despite the numerous syntheses of morphine and its 
congeners, not one is practical enough to be a viable supply for the world's 
demands. One of the long standing goals of the Hudlicky group is the development 
of an efficient, economically viable and environmentally benign synthetic route to 
opium alkaloids. Professor Hudlicky's approach to the synthesis of opiates is unique 
as the chiral starting material is obtained from the enzymatic dihydroxylation of 
arenes. The present thesis discusses the synthesis of ent-neopinone. All strategies 
discussed begin with the toluene dioxygenase dihydroxylation of (3-
bromoethylbenzene providing sufficient quantities of enantiomerically pure cis-
cyclohexadienediol 6 (Figure 13). 
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Figure 13. Retrosynthetic analysis. 
A Mitsunobu inversion of allylic alcohol 5 with an appropriate arene 4 can be used 
to fasten the A ring to the C ring via the ether linkage. Closure B ring can be 
accomplished by an intramolecular Heck reaction thus giving advanced 
intermediate 3. It was envisioned there were three distinct routes to close the D 
and E rings to furnish the pentacyclic core ofneopinone (figure 14). 
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Figure 14. Closure of the D and E ring of neopinone. 
187 
The first approach is a composed of an aldol closure where upon condensation of 
the aldehyde and C-ring enone, the ethylamino bridge would add 1,6 at C-9. The 
second approach consists of closure of the C-9 and C-14 bond by an aza-Prins 
reaction on the iminium species 187. Equally, the third approach would under go a 
y-Mannich clousureon the iminium salt 186. These approaches and the conclusion 
of our chemoenzymatic synthesis of ent-neopinone is discussed herein. 
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3.2 Synthesis of A-ring 
The A-ring synthesis starts from isovanillin 110, which was brominated using 
N-bromosuccinimde to provide bromoisovanillin 188. Protection of the phenol as 
the MOM ether and subsequent wittig elongation using the ylide generated from 
(methoxymethyl)triphenylphosphonium chloride furnished the (E)- and (Z)-enol 
ethers 190. The (E)- and (Z)-enol ethers were exposed to ethylene glycol under 
acidic conditions to give the A-ring fragment 191 in an overall yield of 48%. 
Meov MeO~ Meo~ HO I .& CHO ii MOMO I .& CHO HO I .& CHO ... ... 
Br Br 
110 188 189 
~ii 
MeOW> MeO~ iv 
MOMO 1.& .& OMe HO.& 0 IIIIIIIIE 
Br Br 
191 190 
Reagents and conditions: i) NBS, CHCh, reflux (68%); ii) MOMCl, iPr2NEt, CHzClz, 4°C; (iii) 
CIPh3PCH20CH3, tBuLi, THF, -78°C to 4°C; (iv) (CHzOH)z, pTsOH, THF, reflux (76% over three steps), 
Scheme 23. Synthesis of the A-Ring fragment. 
3.3 Synthesis of C-ring 
Following the previously reported HUdlicky approach to the desired Boc 
carbamate 5,93 the synthesis started with the microbial oxidation of (3-
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bromoethylbenzene 154 using E. coli JM109 (pTDG601A)11 furnishing the cis-
cyclohexadiene diol 6 in 10 g per liter of cell broth (scheme 24). Dimide reduction 
of the distal olefin using potassium azodicarboxylate and acetic acid afforded the 
allylic alcohol 192 in 83% yield. Protection of the diol moiety with acetic anhydride 
and triethylamine provided the bisacetate 172. However in our hands, following 
the previously published protocol, treatment of compound 172 with methylamine 
and potassium carbonate, provided the desired amine 193 in low yields with a 
major contaminate being furan 194, 
Br Br Br Br 
6 6:0H ii 6:0H iii 6:0AC ... ... ... ~ OH OH OAe 
154 6 192 172 
NHMe 
~w 
6:0H + 8:H OH 
193 194 
Reagents and conditions: i) E. coli JM109 (pTDG602) (10gjL); ii) PAD, AcOH, MeOH (80%); iii) AczO, 
NEt3, DMAP, CHzClz (79%); iv) MeNH2, KZC03, THF, -40°C to O°C. 
Scheme 24. Preparation of C-ring 
The obvious solution to this problem was the utilization of an alternative 
protecting group. We chose to protect the diol as its acetonide preventing any 
achnce of furan formation. Treating intermediate 192 with 2,2-diemthoxypropane 
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and catalytic p-toluenesulfonic acid generated the acetonide 195 in 80% yield. 
Following the same amination protocol as before acetonide 195 was smoothly 
converted to methyl amine 196 in 90% yields with no contamination by the furan. 
A one pot hydrolysis of the acetonide followed by protection of the amine provided 
carbamate 180. Regioselective protection of the distal hydroxyl gave the C-ring 
fragment 5 in 31% overall yield. This optimized route allowed for mUltigram scale 
synthesis of the C-ring fragment. 
Br Br Br Br 
6 teOH ii teOH iii .... 6::>< .... .... ~ OH OH 
154 6 192 195 
~Y 
NMeBoc NMeBoc NMeH 
6::>< 6:0H ~ vii 6:0H v,vi II1II OTBS OH 
5 180 196 
Reagents and conditions: i) E. coli JM109 (pTDG602) (10g/L); ii) PAD, AcOH, MeOH (80%); iii) 2,2-
dimethoxypropane, acetone, pTsOH (80%); iv) MeNH2, K2C03, THF, sealed tube (90%); v) 3N HCI, 
EtOH; vi) BOC20, NaHC03, EtOH (72% over two steps); vii) TBSCI, imidazole, CH2Ch, -78°C to 25°C 
(80-88%). 
Scheme 25. Revised route to C-Ring fragment 5. 
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3.4 Generation of the key advanced intermediate 
To couple the A ring fragment 191 and C ring fragment 5 a Mitsunobu reaction 
was envisoned. Exhaustive screening of Mitsunobu conditions (Table 1) were 
performed on the A and C ring fragments. 
NMeBoc MeOW> 
HO.& 0 + 6:0H .... Br OTBS 
191 5 197 
Figure 15. Mitsunobu coupling of A-ring and C-ring fragments. 
Table 1. MitsunC?bu coupling of A-ring and C-ring fragments. 
Entry Azodicarboxylate Solvent Base Temperature Result 
1 DIAD Toluene RT Trace 
2 DIAD CH2Ch RT SM 
3 DIAD Et20 RT SM 
4 DIAD THF RT 44% 
5 DIAD CH3CN RT SM 
6 DIAD THF NEt3 RT 35% 
7 DIAD THF N-methylpiperidine 35% 
8 ADDP THF 29% 
9 DIAD THF -10°C-RT 76% 
The use of diispropyl azodicarboxylate and tri-n-butyl phosphine (Table 1, entry 9) 
with careful control of the temperature during addition was found the give the best 
yield and was scaled upto mUltigram scale (10 g). 
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With the A-ring and C-ring tethered together we investigated conditions 
necessary for the intramolecular Heck reaction. After exhaustive screening it was 
found that the use of tri-tert-butylphospine was abosuletely required (table 2, 
entries 13-17) for the intramolecular Heck reaction. The palladium catalyst was 
found not to playas important of a role, however the use of 
Tris (dibenzylideneacetone) dipalladium(O) (table 2, entry 16) did result in the 
highest yield of 87%. Interestingly under these conditions an inseparable mixture 
ofallylic and homoallylic sHyl ethers 198 and 199 were obtained in a 1:5 ratio. The 
allylic TBS ether is assumed to be from the palladium-mediated isomerization of the 
olefin 199 to 198. 
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Figure 16. Intramolecular Heck reaction of ether 197. 
Table 2. Intramolecular Heck reaction of ether 197. 
Entry Phosehine Palladium Base Additive Result 
1 (p-tolyl)3P Pdz(dba)3 AgZC03 SM 
2 (p-tolyl)3P Pdz(dba)3 NEt3 SM 
3 (o-furylhP Pd(OAc)z AgZC03 SM 
4 ( o-furyl)3P Pd(OAc)z NE~ SM 
5 DPPE Pd(OAc)z AgZC03 SM 
6 DPPE Pd(OAc)z NEt3 AgOTf SM 
7 (o-furyl)3P Pd(OAc)z CSZC03 NiBrz/NaI decomposition 
8 (o-furylhP Pd(OAc)z NEt3 NiBrz/NaI decomposition 
9 DPPF Pd(OAc)z CSZC03 NiBrz/NaI decomposition 
10 DPPF Pd(OAc)z NEt3 NiBrz/NaI decomposition 
11 DPPF Pd(OAc)z AgZC03 Tl(OAc)z SM 
12 tBu3P Pd(OAc)z MeDCHA 19% 
13 tBu3P Pd(OAc)2 (S2(03 740/0 
14 tBu3P Pdz(dba)3 MeDCHA 60% 
15 tBu3P Pdz(dba)3 CSZC03 full conversion 
16 tBu3P Pd2(dbah K2(03 870/0 
17 tBu3P Pd(OAc)2 K2(03 73% 
Treatment of silyl ether 198 and 199 with tetra-n-butylammonium fluoride 
furnished the allylic and homoallylic alcohols 201 and 202 respectively. After the 
sHyl deprotection the isomers where easily separable by column chromatography. 
Oxidation using IBX provided us with access to the key intermediate 204 and its 
isomer 203. 
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Reagents and conditions: i) TBAF, THF, -78°C - RT (83-85%); ii) lEX, EtOAc, reflux. 
Scheme 26. Perparation of advanced intermediates 203 and 204. 
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203 
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Column chromatography of these enones, using either neutralized silica gel or 
alumni a, proved to be poor, resulting in low isolated yields, despite their relative 
purity of the crude product by TLC and lH NMR. Therefore these were used crude 
for subsequent reactions. 
3.5 Attempts to Close Band Dring 
With the advanced intermediates 203 and 204 in hand we set out to 
investigate the various proposed closures of the Band D rings. Treatment of 203 
and 204 with trifluoroacetic acid cleanly gave the [3.3.1] bicyclic compound 205, 
with out any of the expected condensation of the secondary amine with the masked 
aldehyde (scheme 28). 
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203 
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Reagents and conditions: i) TFA, CH2Ch (44-55% over two steps). 
Scheme 28. Formation ofbicyclic adduct 205. 
205 
Despite no evidence for formation of the condensed iminium species 186, we hoped 
that after hydrolysis of the acetal we could force an equilibrium towards the desired 
iminium species 186 by using either basic or acidic conditions. 
With this in mind we screened numerous conditions for the hydrolysis of the 
acetal as seen in Table 3. Ultimately the best result for the hydrolysis was found 
when using oxalic acid in water at 40°C affording the desired aldehyde 206 in 88-
92% yields. 
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Figure 17. Hydrolysis of acetal 205. 
Table 3. Hydrolysis of acetal 205. 
Entry Reagents Solvent Temp Result 
1 HCI MeCNjMeOH 45°C 206 + 207 (30%) 
2 SnC14 CH2Clz RT 206 «10%) 
3 CeCh·7H20, MeCN RT SM 
NaI 
4 PdClz acetone RT - 55°C SM 
5 pPTs H20, acetone RT- 55°C SM 
6 pTsOH 3-pentanone RT - 55°C SM 
7 CAN MeCN, H2O RT- 55°C SM 
8 (C02Hh H2O RT 206 (trace) 
9 (C02Hh H2O 40°C 207 (88-92%) 
It is interesting to note that when treating the acetal with hydrochloric acid in 
acetonitrile and water it afforded a mixture of two aldehydes 206 and 207 in 
various ratios depending on the reaction time. When the homoaldehyde 206 was 
treated under the same conditions it cleanly converted to 207. Out of curiosity we 
investigated what was causing the presence of the "cleaved" aldehyde by screening 
various reaction conditions (Figure 18). 
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Figure 18. Generation of bypro ducts from the hydrolysis of acetal 208. 
Table 4. Generation of bypro ducts from the hydrolysis of acetal 5. 
Entry Reagent Solvent Temperature Result (208:209) 
1 (C02H)2 H2O 40°C 75:25 
2 HCI MeCN, H2O 40°C 22:78 
3 HCI MeCN, H20, degassed 40°C 95:5 
Treatment of the phenol 191 with aquesous oxalic acid at 40 °C afforded a mixture 
of homobenzaldehyde 208 and benzaldehyde 209 in a 3:1 ratio. Where as the 
reaction in aqueous acetonitrile with hydrochloric acid gave the benzaldehyde 209 
as the major product When treated with degassed hydrochloric acid and aqueous 
acetonitrile at 40 °C the major product was primarily the homo benzaldehyde 208. 
Aside from the apparent solvent effects it is obvious that oxygen played a critical 
role in cleavage of the homobenzaldehyde. The proposed mechanism for the 
formation of benzaldehyde 207 is shown in Figure 19. The presence of oxygen in 
the transformation likely involves an oxidation of the benzylic position leading to 
intermediate 210, which is then converted, via 211, to hydroperoxide 212. 
Fragmentation of213 then leads to benzaldehyde 207 and formic acid. 
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Figure 19. Proposed mechanism for the formation of benzaldehyde 207.96 
With aldehyde 206 in hand we attempted to we attempted to force an 
equilibrium towards the desired iminium species 186 in we could close the C9 and 
C14 bond via a ~annich reaction. We anticipated screening various acidic or basic 
conditions could invoke the retro-addition necessary to create the desired iminium 
species 186. However, all conditions screened (Table 5) failed to return any thing 
but the bicyclic precursor 206. It appeared after screening numerous conditions the 
1,4 adduct was a thermodynamic pit preventing iminium formation and any chance 
to close the C9-C14 bond. 
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206 186 ent-codeinone 
Figure 20. Attempts to close the C9-C14 bond via Mannich reaction. 
Table 5. Attempts to close the C9-C14 bond via Mannich reaction. 
Entry Reallents Solvent Temp Result 
1 10% H3P04 H2O RT - 45°C SM 
2 80% AcOH H2O RT - 45°C SM 
3 AcCI MeOH o °C - RT SM 
4 HCI Et20 o °C - RT SM 
5 TMS-CI, tBuOK THF o °C - 45°C SM ' " 
6 AcOH/NaOH pH4 H2O RT SM 
7 AcOH/NaOH pHS H2O RT SM 
8 AcOH/NaOH pH6 H2O RT SM 
9 AcOH/NaOH pH7 H2O RT SM 
10 AcOH/NaOH pH8 H2O RT SM 
Without the formation of the iminium speices necessary for the Mannich 
reaction, we then turned our attention to aza-Prins approach to close the C9-C14 
bond. Starting with the homo allylic alcohol 202 and treating it with trifluoroacetic 
acid in dichloromethane resulted in the formation of two products, the secondary 
amine 214 and the enamine 215 in a 3:1 ratio respectively (scheme 29). 
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ii 1 
Reagents and conditions: i) TFA, CH2Ch (49 - 65% of 214, 10 - 21% of 215); ii) (C02H)2, H20, 40°C 
(88%). 
Scheme 29. Preparation of key intermediate for aza-Prins approach. 
Treating amine 214 with oxalic acid and water at 40°C allowed for clean conversion 
to enamine 215. We then treated the aza-Prins precursor 215 with various 
Brfl1nsted and Lewis acids in hopes to furnish the cyclized product (Table 6). 
------ .... 
211 212 
Figure 21. Investigation of the aza-Prins closure oftheC9-C14 bond. 
Table 6. Investigation of the aza-Prins closure of the C9-C14 bond. 
Entry Reallent Solvent Teml!.erature Result 
1 SC(OTf)3 CHCD3 RT SM 
2 SiOz 100°C SM 
3 85% H3P04 RT- 40°C SM 
4 SnCl4 CHzClz RT SM 
5 SnCl4 toluene RT - 80°C SM 
6 AcOH RT Decomposition 
7 TMSOTf CHzClz o °C - RT SM 
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All attempts resulted in the recovery of starting material or decomposition. Analysis 
by TLC or HPLC showed no compounds matching that of prepared standards. These 
results are similar to Fukuyama's results,97 who envisioned a similar intermediate 
186 upon which molecular modeling studies suggested that the dienone and the 
iminimum cation of the intermediate 187 were situated orthogonally to each 
other.97 Therefore inhibiting the formation of the C9-C14 bond. 
We finally turned our attention to the aldol approach to close the morphine 
skeleton. To test feasibility of the proposed dienone intermediate 185, we 
exchanged the Boc group for the more robust acetyl group (Scheme 30). 
ii,iii 
217 218 
Reagents and conditions: i) a) AcCI, Et3N, CHzC}z, (b) MeONa, MeOH (87%); (ii) IBX, AcOEt, 80°C; iii) 
50% aqueous TFA, toluene, 50°C (22% from 217). 
Scheme 30. Testing the feasibility of aldol approach. 
Acelyation of the secondary amine 214 gave amide 217. Oxidation of the amide 
217 followed by subsequent hydrolysis of the acetal furnished a mixture of 
diastereomeric alcohols 218. Isolation of the alcohols 218 affirmed the aldol 
approach as theses alcohols could be converted to the dienone. 
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3.6 Synthesis of Neopinone 
As our work was nearing completion, Fukuyama97 reported a conceptually 
identical approach to the natural enantiomer of morphine. In his approach he chose 
to protect the amine as the 2,4-dinitrobenzenesulfonyl amide. At this point we 
chose to formalize our synthesis and set out to intercept Fukuyama's intermediate, 
as shown in scheme 31. 
Taking the secondary amine 202 and treating it with 2,4-
dinitrobenzenesulfonyl chloride and Hiinig's base and subsequent oxidation with 
IBX provided us with the sulfonylamide 219. Subjecting intermediate 220 to 
Fukuyama's sequence of treatment with trifluoroacetic acid in toluene followed by 
mesylation afforded the desired mesylate 221. The robust nature of the cyclic 
acetal required longer reaction times to furnish the desired aldol intermediate 
product. Following Fukuyama's conditions we used 1.2 equivalents of 
methanesulfonyl chloride and 1.5 equivalents of Hiinig's base after the 
intramolecular aldol leading to isolation of the mesylate 221 in only 6% yield from 
219. It is expected that traces of ethylene glycol in the reaction mixture are 
contributed to the low yields. 
When the mesylation was performed using excess of both methanesulfonyl chloride 
(4.5 equivalents) and Hiinig's base (5 equivalents) it led to the in situ elimination of 
the mesylate forming a mixture of 222 and 223 in a more respectable yield of 42% 
and 13% respectively, over two steps from 219. The desired enone 222 was 
treated with thiogycolic acid in the presence of triethylamine to furnish ent-
neopinone 1. 1 H NMR and TLC analysis of the reaction mixture confirmed the 
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presence of neopinone 1 matching an authentic sample prepared from thebaine 69 
according to Rapoport's procedure.98 
ii 
202 219 220 
223 222 221 
ent-codeine ... --------
ent-neopinone 1 
Reagents and conditions: i) 2,4-dinitrobenzenesulfonyl -chloride, iPr2NEt, CH2Ch (51%); (ii) IBX, 
AcOEt, 80°C; (iii) (a) 50% aqueous TFA, toluene, 50°C (b) MsCI (4.5 equiv), iPr2NEt (5 equiv), CH2Ch, 
o °C (42% of222 from 219, 13% of223 from 219); (iv) thioglycolic acid, iPr2NEt, CH2C}z, 0 °C. 
Scheme 31. Conclusion of the formal sytnthesis of ent-neopinone. 
To guarantee that the low yields obtained from the cyclic acetal 219 were caused by 
the robust nature of the cyclic acetal, we chose to repeat Fukuyama's sequence with 
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the dimethyl acetal (scheme 32). Treatment of 215 with p-toluenesulfonic acid in 
anhydrous methanol at reflux affored the dimethyl acetal 224. 
215 
ent-neopinone 1 
iv 
liliiii 
ii 
224 
+ 
222 
OMe 
.... 
225 
!iii 
MeO 
0 
221 
Reagents and conditions: i) MeOH, pTsOH, reflux (86%) (ii) IBX, AcOEt, 80°C; (iii) (a) 50% aqueous 
TFA, toluene, 50°C (b) MsCI (4.5 equiv), iPr2NEt (5 equiv), CH2C}z, 0 °C (24% of221 from 224, 28% 
of222 from 224); (iv) thioglycolic acid, iPr2NEt, CH2C}z, O°C. 
Scheme 32. Reproduction of Fukuyama's sequence to morphine. 
Oxdiation of 224 with IBX furnished ketone 225 with an optical rotation of +25.5° 
opposite to that of the natural isomer (-24.2°).97 Treating ketone 225 with 
trfluoroacetic acid followed by mesylation provided the mesylate 221 in 28% yield 
and dienone 222 in 24% yield from 224. This confirmed our suspicion that the 
robust protecting group was the reason for the lower yields. Treatment of the 
mixture of 221 and 222 with thioglycolic acid and Hiinig's base, as reported by 
Fukuyama,97 afforded a full conversion to ent-neopinone 1, which matched with 
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authentic samples. Fukuyama97 reported isomerization of neopinone obtained from 
the cyclization to codeinone followed by reduction of the latter to codeine. 
Threrefore the attainment of ent-neopinone 1 also formalizes the synthesis of ent-
codeinone and ent-codeine. 
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4. Conclusions and Future Work 
In the course of the present studies, we employed the cis-cyclohexadienediol 
obtained from the enzymatic dihydroxylation of j3-bromoethylbenzene in a 15 step, 
from j3-bromoethylbenzene, synthesis of ent-neopinone. The functionalized cis-
cyclohexadienediol was responsible for controlling the stereos electively of the 
crucial Mitsunobu coupling and intramolecular Heck reaction setting the C5 and 
quartenary C13 stereo centers. We also investigated several approaches for 
construction of phenantharene core of morphine alkaloids. Finally settling on a 
sequence consisting of aldol condensation and subsequent l,6-addition. During 
these investigations the key issue was the incompatibility of protecting groups. This 
resulted in poor control of selective deprotection resulting in unintended byproduct 
formation. In future work, proper choice of protecting groups or ideally the use of 
no protecting groups could lead to a shorter and more efficient route. This would 
also allow for further investigation of the Mannich approach, as we could never 
generate the proposed intermediate because of the protecting group 
incompatibility. Another approach to close the C9-C14 bond could be done through 
a carbonyl-ene reaction by treating aldehyde 228 with various Brf{jnsted and Lewis 
acids to possibly furnish the allyl silyl ether 230, which could be converted to ent-
neopinone by a sequence of mesylation, deprotection, oxidation and finally the 1,6 
addition to close the D ring. Aldehyde 228 could be obtained via a similar synthetic 
route to the one discussed previously with the choice of acid stable protecting 
groups such as the FMoc and TIPS. 
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Scheme 33. Proposed carbonyl-ene closure ofC9-C14 bond 
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5. Experimental Section 
General 
Reactions were carried out under inert atmosphere in oven dried glassware unless 
stated otherwise. Solvents were distilled: CH2Clz, DMF, iPr2NEt and pyridine from 
CaH2; MeOH from magnesium methoxide; THF from Na/benzophenone; toluene 
from Na. Qualitative TLC was done with precoated silica gel aluminium sheets (EMD 
silica gel 60 F254); detection by UV or by spraying with "CAM" solution (5 g of 
(NH4)6M07024,4H20, 1 g of Ce(S04)2, 100 ml of 10% H2S04) or 0.5% aqueous KMn04 
solution followed by heating. Column chromatography was performed using silica 
gel SiliaFlash P60 from Silicycle (40-66 ~m). Optical rotation was measured in a 1-
dm cell at 20-25 ·C and 589 nm; concentration c in g/100 ml. IR spectra were 
recorded as ca. 2% solutions in CHCb or as a thin film. IH NMR and 13C NMR spectra 
were recorded at 300 or 600 MHz and 75 or 150 MHz, respectively, and were 
calibrated to the solvent signal or tetramethylsilane; the chemical shifts are 
reported in ppm. Mass spectra were recorded on Kratos/MsI Concept lS mass 
spectrometer at Brock University. Combustion analyses were performed by Atlantic 
Microlabs, Norcross, GA. 
2-(2,2-Dimethyl-3a,6, 7, 7a-tetrahydrobenzo[ d] [1,3]dioxol-4-yl)-N-
methylethanamine (196). 
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A solution of diol 192Error! Bookmark not defined. (45.2g, 205 mmol) in acetone 
400 ml) was treated with 2,2,-dimethoxypropane (37.6 ml, 307 mmol) and pTsOH. 
The reaction was stirred for 4 h at room temperature whereupon the solvent was 
evaporated. The residue was diluted with H20 (50 ml) and extracted with CH2C}z (3 
x 200 ml). The combined organic layers were washed with saturated aqueous 
Na2C03 solution (2 x 20 ml), brine, dried (Na2S04), filtered, and evaporated to yield 
bromide 195 (46.1 g) as a clear colorless oil, which was used without further 
purification. Bromide 195 (10.1 g, 38.3 mmol) was dissolved in THF (35 ml) and 
transferred to a 200 ml thick-walled reaction vessel containing K2C03 (2.64 g, 19.1 
mmol) and a magnetic stirring bar. The reaction vessel was cooled to -40°C, and the 
solution was saturated with methylamine by passing gaseous methylamine from a 
lecture bottle through the solution for 15 min. The reaction vessel was sealed, and 
the mixture was stirred at 25°C for 18 h. The mixture was cooled to -40°C before 
the vessel was opened. Potassium salts were removed by filtration and rinsed with 
CH2C}z. The solvent was evaporated to obtain amine 192 (7.6 g, 94%), which was 
used without further purification. Rf (AcOEt/MeOH/aqueous NH3 7:3:1) 0.3; Mp 
143-147 °C (oxalate salt); [a]D24 = 25.8 (c 1, MeOH); IR (film): n 3324 (w), 2983 (s), 
2932 (s), 2844 (s), 2790 (m), 1674 (m), 1563 (w), 1443 (m), 1367 (s), 1242 (s), 
1221 (s), 1156 (m), 1077 (s), 1030 (s), 869 (m) cm-1; lH NMR (CDCb, 300 MHz): {j 
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5.63 (s, lH); 4.34 (d, l= 5.5 Hz, lH), 4.27 (td, 1 = 5.8,3.2 Hz, lH), 2.78-2.72 (m,2H), 
2.41 (s, 3H), 2.38-2.31 (m, lH), 2.25 (q,l = 7.4 Hz, lH), 2.14 (dddd,l = 9.0, 7.3, 3.9, 
1.7 Hz, lH), 1.91 (t,l = 5.3 Hz, lH), 1.86-1.79 (m, lH), 1.75-1.69 (m; lH), 1.48 (s, lH), 
1.36 (s, 6H); 13C NMR (CDCh, 150 MHz): 0 133.97, 126.58, 108.24, 73.64, 73.47, 
49.81,36.32,34.28,27.91,26.46,25.56,20.80; LRMS-EI (mjz): M+ 196 (3),153 (14), 
136 (5), 44 (100); Anal. caled. for C12H21N02·(COOH)2: C, 55.80; H, 7.69; found C, 
55.75; H, 7.66. 
tert-Butyl 2-((5S,6R)-5,6-dihydroxycydohex-l-enyl)ethyl( methyl) carbamate 
(180). 
180 
A solution of acetonide 196 (7.02 g, 33.2 mmol) in EtOH (40 ml) and H20 (4 ml) was 
treated with 3M HCI (16.6 ml, 49.8 mmol). The reaction mixture was stirred for 4 h, 
treated with NaHC03 (42 g, 500 mmol), and stirred vigorously for 1 h. Then Boc 
anhydride (10.9 g, 49.8 mmol) was added, reaction mixture was stirred for 
additional 4 h, filtered, and evaporated. The residue was diluted with H20 (25 ml) 
and extracted with CH2Clz (3 x 20 ml). The combined organic layers were washed 
with saturated aqueous NH4CI solution (2 x 10 ml), brine, dried (Na2S04), filtered 
and evaporated. Flash column chromatography (hexanesj AcOEt 6:1 ~ 1:2) afforded 
180 (6.48 g, 72%) as a colorless oil. Rf(hexanesjAcOEt 1:1) 0.20; [a]D23 = -95.5° (c 
77 
0.75, CHCh); IR (film): n 3394 (s), 2975 (s), 2931 (s), 1674 (s), 1483 (s), 1353 (s), 
1397 (s), 1366 (s), 1308 (m), 1247 (m), 1220 (m), 1160 (s), 1075 (m), 1053 (m), 
989 (m),945 (w), 919 (w) cm-1; lH NMR (CDCh, 300 MHz): 5.43 (s, IH), 4.87 (s, IH), 
3.96 (s, 2H), 3.56 (s, IH), 2.99 (d,] = 8.8 Hz, IH), 2.91 (s, IH), 2.86 (s, 3H), 2.42-2.30 
(m, IH), 2.18 (d,] = 13.4 Hz, IH), 2.03 (s, 2H), 1.74-1.63 (m, IH), 1.60-1.45 (m, IH), 
1.43 (s, 9H); 13C NMR (CDCh,150 MHz): 157.0, 133.9, 128.8, 79.9, 70.0, 69.8, 48.3, 
34.8,34.0,28.3,25.4,24.8; LRMS-EI (mjz): M+ 271 (1), 197 (3), 171 (1), 153 (9),144 
(29), 110 (23),88 (16), 57 (88), 44 (100); HRMS-EI (mjz): M+ caled. for C14H2SN04: 
271.1784, found 271.1796. 
ten-Butyl 2-((5S,6R)-5-( ten-butyldimetbylsilyloxy)-6-hydroxycyclohex-l-
enyl) ethyl ( metbyl) carbamate (5). 
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A solution of carbamate 180 (7.76 g, 28.6 mmol) and imidazole (3.89 g, 57.2 mmol) 
in CH2Clz (50 ml) was treated with TBSCI (4.75 g, 31.5 mmol) at -78°C, the reaction 
mixture was left to warm slowly to 25°C overnight and treated with saturated 
aqueous NH4CI solution (15 ml). After extraction with CH2Clz (3 x 100 ml), the 
combined organic layers were washed with saturated aqueous NaHC03 solution (20 
ml), brine (20 ml), dried (MgS04), filtered, and evaporated. Flash column 
chromatography (hexanes/AcOEt 3:1) afforded 5 (8.54 g, 77 %) as a clear colorless 
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oil. Rf (CH2Clz/AcOEt, 96:4) 0.47; [a]n24 = -22.6 (c 0.5, CHCb); IR (film): n 3556 (w), 
3475 (w), 2953 (s), 2857 (s), 1692 (s), 1472 (s), 1392 (s), 1253 (s), 1085 (s) cm-1; lH 
NMR (CDCb, 600 MHz, mixture ofrotamers): 6 5.54 (s, lH), 5.52 (s, lH), 3.98 (s,lH), 
3.90 (s, lH), 3.79 (s, lH), 3.77 (s, lH), 3.26-3.20 (m, 2H), 2.85 (s, 3H), 2.82 (s,3H), 
2.39-2.32 (m, 2H), 2.30-2.23 (m, 2H), 2.13 (br s, 2H),l.98 (br s, 2H) 1.80-1.72 (m, 
2H),1.54 (s, 2H),l.44 (s,18H), 0.9 (s,18H), 0.11 (s, 6H), 0.10 (s, 6H); 13C NMR (CDCb, 
150 MHz): 6 155.7, 134.8, 126.6, 79.0, 71.0, 68.8, 48.4, 47.2, 34.1, 33.3, 32.8, 28.4, 
25.8, 25.4, 25.3, 24.3, 24.1, 18.1, -4.4, -4.8; LRMS-EI (mjz): M+ 228 (21), 197 (21), 
136 (12), 74 (22), 73 (15), 57 (63), 44 (100); HRMS-EI (mjz): [M-57]+ calcd. for 
C12H30N04Si: 328.1944, found 328.1946; Anal. calcd for C2oH39N04Si: C, 62.10, 
H,10.22; found C, 62.29, H,10.19. 
2-Bromo-3-(1,3-dioxolan-2-ylmethyl)-6-methoxyphenol (191). 
Meo~ 9) 
HO~O 
Br 
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A solution of bromoisovanillin 110 (10.0g, 43.4 mmol) in CH2Clz (300 ml) was 
cooled to 0 °C and treated with iPr2NEt (15.1 ml, 86.7 mmol) and MOM-CI (4.94 ml, 
65.1 mmol). Reaction mixture was stirred for 3 h while the light yellow solution 
turned clear. The reaction mixture was diluted with H20 (100 ml), the layers were 
separated and the aqueous layer was extracted with AcOEt (3 x 40 ml). The 
combined organic layers were washed with brine, dried (MgS04), filtered, and 
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evaporated to yield crude 188 as a light yellow/brown solid (12.2 g) which was 
used without further purification. Rf (hexanes/ AcOEt 1: 1) 0.69. 
A solution of Ph3P+CH20CH3CI- (23.1 g, 67.2 mmol) in THF (125 ml) was cooled to -
78°C, treated with tBuLi (35.9 ml, 61.1 mmol) dropwise over 10 min, and stirred for 
15 min. The solution was warmed to 0 °C and treated with crude 188 (16.3 g, 61.1 
mmol) in THF (17 ml) dropwise over 5 min while the deep orange solution turned 
to a deep yellow suspension. The suspension was refluxed for 3.5 h, cooled to 25°C, 
diluted with AcOEt (100 ml), and washed with H20 (100 ml). The aqueous layer was 
extracted with AcOEt (3 x 50 mI) and the combined organic layers were washed 
with brine, dried (MgS04), filtered, and evaporated to yield crude 189 as a yellow 
solid (30.8 g) which was used without further purification. 
A solution of crude 189 (32.2 g, 106 mmol) in THF (300 ml) was treated with pTsOH 
(10.1 g, 53.0 mmol), ethylene glycol (29.6 ml, 530 mmol), and refluxed for 2 h. 
Reaction mixture was cooled to 25°C, concentrated, diluted with AcOEt (150 ml), 
and washed with H20 (2 x 20 mIl. Organic layer was washed with brine, dried 
(MgS04), filtered and evaporated. The residue was dissolved in CH2Clz (100 ml) and 
extracted with 0.5M NaOH (3 x 10 mI). The combined aqueous layers were 
neutralized with 1M HCI to pH 7 and extracted with AcOEt (3 x 15 ml). Combined 
organic layers were washed saturated aqueous NaHS03 solution (5 x 15 ml), brine, 
dried (MgS04), filtered and evaporated to yield 191 (16.2 g, 76% from 110) as a 
light yellow solid. Sample for analysis was recrystallized from AcOEt/hexanes. Rf 
(hexanes/AcOEt 1:1) 0.59; Mp 118-120 °C (AcOEt/hexanes); IR (CHCb): n 3370 (w), 
2959 (w), 2892 (w), 1607 (w), 1577 (w), 1490 (s), 1465 (w), 1441 (m), 1404 (w), 
80 
1362 (w), 1336 (w), 1283 (s), 1232 (m), 1199 (w), 1169 (w), 1130 (m), 1034 (s), 
986 (w), 942 (w), 820 (w), 802 (w) cm-1; lH NMR (CDCh, 300 MHz): 6.88 (d,] = 8.3 
Hz, Ar H), 6.79 (d,] = 8.3 Hz, lH), 5.95 (s, exchange with D20, lH), 5.12 (t,] = 4.9 Hz, 
lH), 4.03-3.80 (m, 4H), 3.89 (s, 3H), 3.09 (d,] = 4.9 Hz, lH); 13C NMR (CDCb, 150 
MHz): B 145.97, 143.20, 128.86, 111.36, 122.13, 109.66, 103.51, 65.05, 56.41,40.17; 
LRMS-EI (m/z): M+ 289 (1), 73 (100), 45 (14); HRMS-EI (m/z): M+ caled. for 
CllH13Br04: 287.9997, found 287.9994; Anal. caled. for CllH13Br04: C, 45.70, H, 4.53; 
found: C, 45.99, H, 4.47. 
tert-Butyl 2-((5' S,6' 5)-6' -(3" -((1,3-dioxolan-2-yl)metbyl)-2" -bromo-6"-
metboxyphenoxy)-5'-(tert-butyldimetbylsilyloxy)cydohex-1'-
enyl)etbyl(metbyl)carbamate (197). 
A Br 
:6NMeBOC MeO 0 ~ TBSO"'" 
197 
An orange solution of DIAD (7 mI, 35.6 mmoI) in degassed THF (45 mI) was cooled 
to -10°C and treated with PBU3 (9.5 mI, 38.5 mmoI) at one portion. The resulting 
pale yellow solution was stirred for 25 min at -10°C and transferred over 35 min 
into a chilled (4°C) solution ofaleohol5 (10.6 g, 27.4 mmoI) and phenol 191 (8.7 g, 
30.2 mmoI) in degassed THF (90 mI). The mixture was allowed to reach 25°C, 
81 
stirred for 12 h, and evaporated. The residue was adsorbed on silica gel and 
subjected to chromatography (hexanesjAcOEt 8:1) obtain 197 (13.8 g, 76%) and 
recovered phenol 191 (664 mg, 8%). Data/or 197: Yellow oil; Rf (hexanesjAcOEt 
2:1) 0.75; [a]D20 = + 43.7 (c 0.125, CHCb); IR (CHCb): n 3294 (w), 2930 (s), 2857 
(m), 1736 (w), 1697 (s), 1594 (w), 1482 (s), 1441 (m), 1393 (m), 1365 (m), 1293 
(m), 1252 (s), 1171 (s), 1137 (s), 1105 (m), 1085 (m), 1035 (s), 1007 (m), 943 (w) 
cm·1; 1H NMR (CDCb, 600 MHz, two rotamers): 7.04 (d,] = 8.3 Hz, lH), 6.83 (d,] = 8.3 
Hz, lH), 5.80, 5.77 (2 br. s, lH), 5.06 (t,] = 4.9 Hz, lH), 4.48 (hr. s, lH), 4.00-3.92 (m, 
3H), 3.87-3.78 (m, 2H), 3.83 (s, 3H), 3.55 (br. s, 0.4H), 3.41 (br. s, 0.6H), 3.22-3.15 
(m, lH), 3.13 (dd,] = 14.0,4.5 Hz, lH), 3.07 (dd,] = 14.0,5.3 Hz, lH), 2.81 (hr. s, 3H), 
2.52 (br. s, 0.4 H), 2.46 (br. s, 0.6H), 2.42-2.35 (m, lH), 2.25-2.13 (m, 2H), 2.02-1.94 
(m, lH), 1.67-1.60 (m, lH), 1.44 (s, 9H), 0.72 (s, 9H), -0.18, -0.21 (2 s, 6H); 13C NMR 
(CDCb, 150 MHz, 2 rotamers): 155.9, 155.7, 152.0, 144.6, 131.4, 129.2, 121.3, 131.4, 
126.2, 111.1, 103.5, 79.8, 79.6, 79.1, 67.5, 65.0, 55.8,49.1,48.3,40.6,35.3,35.1,33.7, 
32.9,28.6,25.8,25.3,20.8, 18.1, -5.1; LRMS-EI (mjz): M+656 (1), 368 (8),312 (45), 
268 (39), 237 (52), 180 (8), 136 (28), 105 (10), 73 (100), 57 (58),44 (35); HRMS-EI 
(mjz): M+ calcd. for C31Hs1BrN07Si: 656.2540, found 656.2595; Anal. calcd. for 
C31Hs1BrN07Si: C, 56.70; H, 7.67; found C, 56.95; H, 7.77. 
ten-butyl 2-((5aS,6S, 9aR)-1-((1,3-dioxolan-2-yl)metbyl)-6-( ten-
butyldimetbylsilyloxy)-4-metboxy-5a,6,9, 9a-tetrahydrodibenzo [b,dl furan-9a-
yl)etbyl(metbyl)carbamate (198). And ten-ButyI2-((5aS,6S,9aR)-1-((1,3-
82 
dioxolan-2-yl)methyl)-6-(tert-butyldimethyl-silyloxy)-4-methoxy-5a,6,7,9a-
tetrahydrodibenzo[b,d]furan-9a-yl)ethyl(methyl)- carbamate (199) 
198 199 
A solution of 197 (6.38 g, 9.7 mmol) in degassed toluene (60 ml) was treated with 
K2C03 (2.01 g, 14.6 mmol), Pd2(dba)3 (888 mg, 0.97 mmol), and tBu3P (393 mg, 1.94 
mmol), immersed in a preheated oil bath (110°C), and stirred for 16 h. The reaction 
mixture was filtered through a plug of Celite (washing with CHzClz) and evaporated. 
Flash column chromatography (hexanes/AcOEt 4:1) afforded an inseparable 
mixture of 199 and 198 (199/198 ~ 5:1, 4.82 g, 86%) as a brown oil. Rf 
(hexanes/AcOEt 2:1) 0.59; [a]oZO = +34.8 (c 1.00, CHCh); IR (CHCh): n 3010 (w), 
2956 (m), 2931 (m), 2895 (w), 2857 (w), 1730 (w), 1683 (m), 1626 (w), 1584 (w), 
1506 (m), 1482 (w), 1472 (w), 1438 (w), 1401 (w), 1394 (w), 1367 (w), 1321 (w), 
1282 (w), 1258 (m), 1221 (s), 1216 (s), 1213 (s), 1210 (s), 1155 (m), 1127 (m), 
1048 (w), 1009 (w) cm-l; lH NMR (CDCh, 300 MHz): 0 6.78 (d,] = 8.3 Hz, lH), 6.72 
(d,] = 8.3 Hz, lH), 6.01-5.97 (m, lH), 5.73-5.68 (m, lH), 5.05 (m, lH), 4.45 (m, lH), 
4.01 (m, 2H), 3.90-3.86 (m, 3H), 3.82 (s, 3H), 3.07 (m, lH), 3.00-2.88 (m, 2H), 2.77 
(s, 3H), 2.28-2.18 (m, lH), 2.13-1.95 (m, lH), 1.92-1.83 (m, 2H), 1.57 (m, 2H), 1.43 
(s, 9H), 0.89 (s, 9H), 0.13 (s, 3H), 0.01 (s, 3H); l3C NMR (CDCh, 150 MHz): 0 155.5, 
146.1, 143.9, 132.3, 129.4, 124.8, 123.1, 111.7, 104.7, 104.5, 89.8, 79.4, 68.4, 65.0, 
83 
64.9,55.8,51.4,45.2,37.5,36.3,35.4,34.2,30.8, 29.7, 28.4, 25.8, 25.7, 18.1; LRMS-EI 
(mjz): 310 (7), 237 (1), 184 (10), 139 (4), 91 (22), 73 (66), 57 (80), 43 (100); 
HRMS-EI (mjz): M+ calcd. for C31H49N07Si: 575.3278, found 575.3276. 
tert-butyl 2 -(( 5aS,6S, 9aR)-1-((1,3-dioxolan-2-yl)metbyl)-6-hydroxy-4-
methoxy-5a,6, 9, 9a-tetrahydrodibenzo[b,d]furan-9a-
yl)etbyl(metbyl)carbamate (201). and tert-ButyI2-((5aS,6S,9aR)-1-((1,3-
dioxolan-2-yl)metbyl)-6-hydroxy-4-metboxy-5a,6, 7, 9a tetrahydrodibenzo 
[b,d]furan-9a-yl)etbyl(metbyl)carbamate (202) 
MeO 
201 202 
A solution of 199 and 198 (199 /198 ~ 5: 1, 4.82 g, 8.34 mmol) in THF (50 ml) was 
cooled to 0 °C and treated with a 1.0M solution ofTBAF in THF (12.6ml, 12.6 mmol). 
The mixture was stirred for 16 h at 25°C, diluted with AcOEt (40 ml), and washed 
with H20 (25 ml). The aqueous layer was extracted with AcOEt (3 x 45 ml) and the 
combined organic layers were washed with brine, dried (Na2S04), filtered, and 
evaporated. Flash column chromatography (hexanes/AcOEt4:1-+ 1:1) afforded 201 
(593 mg, 15%) as a light yellow foam and 202 (3.14 g, 82%) as a light yellow foam. 
Datafor 201: Rr (hexanes/AcOEt 1:2) 0.58; [a]D20 = +11.7 (c 1.00, CHCb); IR (CHCb): 
n 3596 (w), 3024 (w), 3010 (m), 2979 (m), 2935 (m), 2895 (m), 2840 (w), 1729 (w),· 
1683 (s), 1626 (w), 1585 (w), 1507 (s), 1482 (m), 1463 (m), 1453 (m), 1436 (m), 
84 
1401 (m), 1367 (m), 1344 (w), 1320 (w), 1282 (m), 1167 (s), 1154 (s), 1097 (m), 
1047 (m), 1020 (m), 987 (m) em-1; 1H NMR (CDCh, 600 MHz, 2 rotamers): 6 6.85 (d, 
]= 8.4 Hz, lH), 6.75 (d,]= 8.4 Hz, lH), 5.94 (br. s, lH), 5.89 (br. s, lH), 5.07 (br. s, lH), 
4.36 (br., d,]= 6.4 Hz, lH), 4.30-4.25 (m, lH), 4.02-3.95 (m, 2H), 3.90-3.80 (m, 2H), 
3.85 (s, 3H), 3.24 (ddd,] = 13.9,12.3,4.0 Hz, lH), 2.98 (dd,] = 14.4,4.3 Hz, lH), 2.96-
2.90 (m, lH), 2.84-2.60 (m, 3H), 2.46 (d,]= 15.1 Hz, lH), 2.15-2.00 (m, lH), 1.92-
1.77 (m, lH), 1.41 (s, 3H); 13C NMR (CDCh, 150 MHz, 2 rotamers): 6 155.56, 146.94, 
143.37, 131,75, 124.85, 130.52, 127.49, 123.41, 111.62, 104.76,92.96, 79.65, 70.39, 
65.09, 65.01, 55.93, 48.60, 45.48, 40.08, 35.64, 35.48, 34.43, 28.58; LRMS-FAB 
(m/z): [M+H]+ 462 (7), 344 (38), 285 (17), 241 (9), 159 (7), 103 (36), 73 (100), 57 
(73); HRMS-FAB (m/z): [M+H]+ ealed. for C2sH36N07: 462.2492, found: 462.2428. 
Data for 202: Rf (hexanesj AeOEt 1:2) 0.26; [a]D20 +9.5 (c 3.2, CHCh); IR (film): n 
3629 (m), 3018 (s), 1732 (m), 1683 (s), 1625 (w), 1584 (w), 1507 (m), 1400 (m), 
1367 (m), 1318 (w) 1280 (m), 1216 (s), 1156 (m), 1097 (m), 1047 (m), 978 (w) em-
1; 1H NMR (CDCh, 300 MHz, 2 rotamers): 66.81 (d,] =8.3 Hz, lH), 6.74 (d,] = 8.3 Hz, 
lH), 6.03 (dd,] = 9.8, 1.5 Hz, lH), 5.78 (ddd,] = 9.8, 5.7, 2.3 Hz, lH), 5.04 (dd,j= 6.0, 
3.8 Hz, lH), 4.55-4.37 (br. s, lH), 4.05-3.95 (m, 2H), 3.90-3.80 (m,.2H); 3.85 (s,3H), 
3.47-3.20 (m, lH), 3.06 (dd,] = 14.3, 3.4 Hz, lH), 2.94-2.82 (m, lH), 2.89 (dd,] = 
14.3, 6.0 Hz, lH), 2.77 (s, 3H), 2.45-2.30 (m, lH), 2.19-2.03 (m, lH), 2.03-1.78 (m, 
2H), 1.43 (s, 9H); 13C NMR (CDCh, 150 MHz): 6 155.61, 145.76, 144.18, 129.29, 
125.10, 129.49, 124.66, 123.92, 111.80, 104.67, 90.64, 90.12, 79.67, 68.18, 65.10, 
65.06, 56.03, 51.84, 36.59, 34.41, 29.41, 28.61; LRMS-EI (m/z): M+461 (6),388 (3), 
340 (8),285 (16),271 (6),241 (2),213 (8),142 (31),103 (20),84 (31),73 (100), 57 
85 
(81); HRMS-EI (m/z): M+ calcd. for C2sH3SN07: 461.2414, found 461.2414; Anal. 
calcd. for C2sH3SN07: C, 65.06; H, 7.64; found C, 64.94; H, 7.67. 
ten-Butyl 2-((5aS,9aS)-1-((1,3-dioxolan-2-yl)metbyl)-4-metboxy-6-oxo-
5a,6, 9,9a-tetrahydrodibenzo [b,d]furan-9a-yl) etbyl(metbyl) ca rbamate (203). 
203 
A solution of alcohol 201 (229 mg, 0.496 mmol) in DMF (10 ml) was cooled to 0 °C 
and treated with IBX (139 mg, 0.496 mmol). The reaction mixture was stirred for 16 
h at 25°C, diluted with H20 (4 ml), and the layers were separated. The aqueous 
layer was extracted with CHCb (3 x 8 ml). The combined organic layers were 
washed with brine, dried (Na2S04), filtered, and evaporated. Flash column 
chromatography (hexanes/AcOEt, 3:1 ~ 1.5:1) afforded 201 (12 mg, 5%) as a light 
yellow foam and 203 (159 mg, 70%) as a light yellow oil. Rf (hexanes/AcOEt 1:2) 
0.32; [a]D20 = + 91.3° (c 1.415, CHCb); IR (film): n 2979 (w), 1685 (s), 1625 (w), 
1507 (m), 1393 (w), 1366 (w), 1284 (w), 1148 (m), 1044 (w) cm-1; lH NMR (CDCb, 
300 MHz): 6 6.92 (m, IH), 6.82 (d,]= 8.4, IH), 6.73 (d,]= 8.4, IH), 6.20 (d,]= 9.6, IH), 
5.05 (t,]= 4.5, IH), 4.66 (br s, IH), 3.98-3.88 (m, 2H), 3.87-3.79 (m, 6H), 3.34-3.24 
(m, IH), 3.17-3.03 (m, IH), 3.03-2.94 (m, 2H), 2.88-2.82 (m, IH), 2.77 (s, 4H), 2.15-
2.09 (m, 2H), 1.42 (s, 9H); l3C NMR (CDCb, 150 MHz): 6 155.36, 148.63, 147.28, 
143.69, 128.96, 124.57, 124.04, 112.52, 104.55, 86.31, 79.80, 65.03, 64.97, 60.39, 
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56.05, 49.62, 45.23, 38.45, 35.77, 34.27, 28.45, 21.05, 14.20; LRMS-EI (mjz): M+ 
386(2), 359(12), 301(21), 257(14), 216(5), 190(4), 149( 4), 103(7), 84(20), 
73(100), 57(33), 43(82); HRMS-EI (mjz): M+ caled. for CZSH33N07: 459.2257, found 
459.2260. 
tert-Butyl 2-((5aS,6S,9aR)-1-((1,3-dioxolan-2-yl)metbyl)-6-hydroxy-4-
metboxy-5a,6, 7, 9a-tetrahydrodibenzo [b,d] furan-9a-
yl)etbyl(metbyl)carbamate (204). 
204 
A solution of 202 (499 mg, 1.08 mmol) in AcOEt (20 ml) was treated with IBX (457 
mg, 1.63 mmol), the resulting suspension was stirred for 6 h at 80°C, and cooled to 
o °C. Filtration through Celite (washing with cold AcOEt) afforded crude 204 (601 
mg) which was used in the next step without further purification. Rr 
(hexanesJAcOEt 1:1) 0.35; IR (CHCb): n 3025 (w), 3010 (m), 2979 (m), 2934 (m), 
2894 (w), 2840 (w), 1736 (m), 1683 (s), 1627 (w), 1583 (w), 1508 (m), 1481 (m), 
1462 (m), 1454 (m), 1428 (m), 1399 (m), 1367 (m), 1319 (w), 1283 (s), 1168 (s), 
1154 (s), 1092 (w), 1078 (w), 1042 (m), 1017 (m), 984 (w), 944 (w), 909 (w) cm-l; 
lH NMR (CDCb, 300 MHz): 8 6.84 (d,l = 8.3 Hz, lH), 6.76 (d,l = 8.3 Hz, lH), 6.03 (br. 
s, lH), 5.81 (dt, I = 9.8, 3.8 Hz, lH), 5.03 (br. t,l ~ 4.5 Hz, lH), 4.99 (br. s, 0.33H), 4.75 
(hr. s, 0.66H), 4.03-3.94 (m, 2H), 3.94-3.80 (m, 2H), 3.87 (s, 3H), 3.30-2.87 (m,6H), 
87 
2.81 (s, 3H), 2.23-2.02 (m, 2H), 1.44 (s, 9H); HC NMR (CDCb, 150 MHz, 2 rotamers): 
B 146.90, 143.96, 129.75, 129.40, 124.56, 124.16, 124.16, 123.64, 112.49, 104.57, 
87.81, 87.47, 79.93, 65.08, 56.24, 45.34, 44.83, 37.64, 37.20, 36.43, 34.40, 34.44, 
28.58; LRMS-FAB (mjz): M+ 459 (1),85 (67),83 (100), 73 (81),57 (27),47 (19),44 
(22),41 (18); HRMS-EI (mjz): M+ calcd. for C2sH33N07: 459.2257, found 459.2252. 
(45, 6a5, IlbR)-11-(1,3-Dioxolan-2-ylmethyl)-8-methoxy-3-methyl-2,3,4,5-
tetra-hydro-1H-4,llb-methano[1 ]benzofuro[3,2-d]azocin-6-one (205). 
MeO 
o 
205 
A solution of crude 204 (theoretical content 1.08 mmol) in CH2Ch (8 ml) was 
treated with TF A (2 ml), the mixture was stirred for 1 h, and poured into saturated 
aqueous Na2C03 solution (30 ml) containing solid Na2C03 (6 g). The biphasic 
mixture was stirred for 10 min (effervescence), diluted with CR2Ch (30 ml) and the 
layers were separated. The aqueous layer was extracted with CH2Ch (3 x 30 ml). 
The combined organic layers were washed with brine (40 ml), dried (Na2S04), and 
evaporated. Flash column chromatography (AcOEt/MeOH 6:1) afforded 205 (217 
mg, 56% from 202) as a brown foam. Rf(CHCb/MeOH/aqueous NH3 92:8:1) 0.52; IR 
(CRCb): n 3021 (m), 3011 (m), 2959 (m), 2935 (m), 2893 (m), 2794 (w), 1727 (s), 
1628 (w), 1584 (w), 1508 (s), 1475 (w), 1462 (w), 1452 (m), 1452 (m), 1437 (m), 
88 
1401 (m), 1377 (w), 1359 (w), 1340 (w), 1283 (s), 1267 (m), 1167 (m), 1142 (s), 
1115 (s), 1017 (s), 990 (m), 951 (w), 944 (w), 924 (w) cm-1; lH NMR (CDCb, 300 
MHz): 6 6.82 (d,] = 8.5 Hz, lH), 6.73 (d,] = 8.5 Hz, lH), 5.02 (t,] = 4.8 Hz, lH), 4.72 
(s, lH), 4.00-3.90 (m, 2H), 3.90-3.79 (m, 2H), 3.83 (s, 3H); 3.51 (m, lH), 3.01 (dd,] = 
14.5,4.7 Hz, lH), 2.97 (dd,] = 14.5,5.1 Hz, lH), 2.96-2.85 (m, lH), 2.71-2.55 (m, 2H), 
2.50-2.30 (m, 2H), 2.34 (s, 3H), 1.85 (br. d,] = 12.9 Hz, lH), 1.70 (dt,] = 13.2,2.8 Hz, 
lH); HC NMR (CDCb, 75 MHz): 6 205.76, 147.02, 143.69, 131.30, 124.72, 124.13, 
111.98, 104.81,89.16,65.09, 55.98,49.39,46.92,42.96, 36.28, 35.67, 34.25; LRMS-
EI (mjz): 290 (18), 288 (18),217 (21),215 (22), 74 (11), 73 (100),45 (41); HR MS-
EI (mjz): M+ caled. for C2oH2SNOs: 359.1733, found 359.1740. Anal. caled. for 
C2oH2SNOs: C, 66.83; H, 7.01; found C, 66.83; H, 7.02. 
[(4S,6aS,llbR)-8-Methoxy-3-methyl-6-oxo-2,3,4,5,6,6a-bexabydro-1H-4,11b-
methano[1]benzofuro[3,2-d]azocin-ll-yl]acetaldebyde (206). 
206 
A mixture of205 (231 mg, 0.643 mmol) and oxalic acid (159 mg, 1.77 mmol) in H20 
(6 mI) was stirred at 40 DC for 13 h, cooled to 25 DC, poured into saturated aqueous 
NaHC03 solution (15 ml), and extracted with CHCb (3 x 15 mI). The combined 
organic layers were washed with brine (15 mil, dried (MgS04), and evaporated to 
89 
get crude aldehyde 206 (227 mg) which was used without further purification. A 
sample was purified by flash column chromatography (CHCbjMeOHjaqueous NH3 
92:8:1). Colorless oil; Rr (CHCbjMeOHjaqueous NH3 92:8:1) 0.52; IH NMR (CDCb, 
600 MHz, crude): 6 9.70 (br. t,] = 1.9 Hz, lH), 6.79 (d,] = 8.3 Hz, lH), 6.66 (d,] = 8.3 
Hz, lH), 4.76 (s, lH), 3.86 (s, 3H), 3.78 (dd,] = 17.0, 1.9 Hz, lH), 3.72 (dd,] = 17.0, 1.9 
Hz, 1H), 3.53-3.48 (m, lH), 2.96-2.91 (m, lH); 2.68 (d,]= 17.4 Hz, lH), 2.50-2.30 (m, 
3H), 2.35 (s,3H),2.19 (br. d,]= 12.8 HZ,lH), 1.89-1.84 (m, lH), 1.71 (dt,]~ 12.8,2.3 
Hz, lH); LRMS-EI {mjzJ: M+ 315 (3), [M-OH]+ 298 (21), [M-H20]+ 297 (100),282 
(11),229 (18), 214 (20), 188 (10),43 (11),42 (14); HRMS-EI (mjzJ: M+calcd. for 
C18H21N04: 315.1471, found 315.1469. 
(4S,6aS,11bR)-8-Methoxy-3-methyl-6-oxo-2,3,4,5,6,6a-hexahydro-1H-4,11b-
methano[l ]benzofuro[3,2-d]azocine-ll-carbaldehyde (207). 
207 
A solution of crude aldehyde 206 (4 mg) in MeCN (0.2 mI) and H20 (0.2 ml) was 
treated with concentrated HCI until the pH reached 1, the mixture was stirred at 40 
eC for 22 h, cooled to 25 ec, poured into saturated aqueous NaHC03 solution (5 ml), 
and extracted with CHCh (4 x 5 mIl. The combined organic layers were washed with 
brine (5 mI), dried (MgS04), and evaporated to furnish crude 207 (4 mg). A pure 
sample was obtained by flash column chromatography (AcOEt/MeOH 7:1 -+ 5:1). Rf 
90 
(AcOEt/MeOH 5:1) 0.33; IR (CHCb): n 3027 (w), 3012 (w), 2963 (m), 2964 (m), 
2845 (w), 2789 (w), 2745 (w), 1726 (s), 1691 (s), 1615 (s), 1574 (m), 1507 (m), 
1447 (m), 1438 (m), 1410 (w), 1377 (w), 1340 (w), 1293 (s), 1270 (m), 1260 (m), 
1169 (m), 1144 (m), 1117 (m), 1102 (m), 1066 (w), 1054 (w), 1017 (m), 981 (w), 
953 (w), 927 (w) cm-1; lH NMR (CDCb, 300 MHz): 09.91 (s, lH), 7.43 (d,] = 8.3 Hz, 
lH), 6.91 (d,] = 8.3 Hz, lH), 4.93 (s, lH), 3.95 (s, 3H), 3.51-3.46 (m, lH), 3.05 (td,] = 
12.5, 5.3 Hz, lH), 2.95 (br. dd,] = 12.8,4.2 Hz lH), 2.85 (br. d,] = 12.1 Hz, lH), 2.67 
(hr. d,] = 17.4 Hz, lH); 2.53 (br. t,] = 11.3 Hz, lH); 2.42 (dd,] = 17.0,8.7 Hz, lH), 
2.37 (s, 3H), 1.70 (br. d,] = 12.8 Hz, lH), 1.54 (br. dt,] = 12.8, 2.6 Hz, lH); 13C NMR 
(CDCb, 150 MHz): 0 206.07, 190.54, 150.03, 148.00, 132.57, 126.45, 131.08, 110.88, 
90.22,56.17, 55.76,50.45,46.38,43.10, 34.34, 34.18; LRMS-EI (mJz): M+ 301 (23), 
273 (23),272 (20),258 (34),231 (29),230 (72),215 (40), 167 (30), 150 (26), 149 
(100),112 (21),83 (28), 71 (36), 70 (84),69 (20),57 (52),55 (26),44 (41),43 (49), 
41 (31); HRMS-EI (mJz): M+ caled. for C17H19N04: 301.1314, found 301.1310. 
(4S,4aS,9bR)-9-((1,3 -Dioxolan -2 -yl)metbyl)-6-metboxy-9b-(2-
(metbylamino )etbyl)-3,4,4a,9b-tetrahydrodibenzo[b,d]furan-4-ol (214) and 
(4aS,5S,8aR,E)-3-Metboxy-ll-metbyl.,4a,5,6,9,10,ll-
hexahydrobenzo[2,3]benzo-furo[3,4-de]azocin-5-ol (215). 
MeO 
214 215 
91 
A solution of carbamate 202 (514 mg, 1.13 mmol) in CHzClz (1 ml) was cooled to 0 
°C and treated with TFA (0.25 ml) over 10 min. The mixture was stirred for 15 min, 
concentrated, diluted with saturated aqueous NaZC03 solution (3 ml) and extracted 
with CHzClz (3 x 5 ml). The combined organic layers were washed with brine (5 ml), 
dried (MgS04), and evaporated. Flash column chromatography 
(CHzClzjMeOHjaqueous NH3 100:10:1) afforded secondary amine 214 (202 mg, 
0.559 mmol, 49%) and enamine 215 (34 mg, 10 %). 
Data/or 214: Colorless oil; Rf (CHzClzjMeOHjaqueous NH3 100:10:1) 0.33; [a]oZO = 
+22.8 (c 0.875, CHCb); IR (CHCb): n 3588 (w), 3027 (w), 2936 (m), 1624 (m), 1582 
(m), 1506 (s), 1438 (m), 1280 (s), 1131 (s), 1099 (s), 1043 (s), 975 (s) cm-l; lH NMR 
(CDCb, 600 MHz): 8 6.80 (d,] = 8.4 Hz, lH), 6.72 (d,] = 8.4 Hz, lH), 6.00 (d,] = 9.6 
Hz, lH), 5.04 (dd,] = 5.4,4.2 Hz, lH), 4.65 (d,] = 6.0 Hz, lH), 4.04-4.00 (m, 3H), 3.88-
3.85 (m, 2H), 3.03 (dd,] = 14.4, 5.4 Hz, lH), 2.92 (dd,] = 14.4, 5.4 Hz, lH), 2.78-2.71 
(m, lH), 2.60-2.54 (m, lH), 2.38 (s, lH), 2.31 (d, ]= 1.8 Hz, lH), 2.15-2.12 (m,2H), 
2.02-2.00 (m, lH); 13C NMR (CDCb, 150 MHz): 8 145.87, 143.71, 133.12, 129.68, 
125.15, 124.54, 123.50, 111.33, 104.53, 89.46, 66.77, 64.94, 64.92, 55.82, 47.70, 
41.46, 39.19, 36.82, 36.24, 35.87, 28.74; LRMS-FAB (mjz): [M + H]+ 362 (100), 73 
(45), 59 (32), 45 (12),44 (40); HRMS-EI (mjz): M+ caled. for CzoHzzNOs: 361.1889, 
found 361.1891. Anal. caled. for CZOHZ7NOs: C, 66.46; H, 7.53; found C, 66.17; H, 7.56. 
Data/or 215: Ocre solid; Rf (CHzClzjMeOHjaqueous NH3 100:10:1) 0.57; IR (CHCb): 
n 3593 (w), 3027 (w), 3008 (m), 2958 (m), 2932 (m), 2854 (w), 2801 (w), 1723 (w), 
1690 (w), 1666 (w), 1627 (s), 1572 (w), 1503 (s), 1464 (m), 1438 (m), 1427 (m), 
1415 (m), 1380 (m), 1339 (w), 1285 (s), 1263 (s), 1160 (m), 1103 (s), 1087 (s), 
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1074 (m), 1055 (s), 1020 (m), 1005 (m), 976 (w), 968 (w), 955 (w), 908 (w) em-i. iH 
NMR (CDCb, 300 MHz): 6 6.66 (d,] = 8.5 Hz, lH), 6.58 (d,] = 8.5 Hz, lH), 6.53 (dd,] = 
10.2,3.0 Hz, lH), 5.75 (d,] = 9.4 Hz, lH), 5.64 (ddd,] ~ 10.2,6.4, 1.9 Hz, lH), 4.88 (d, 
] = 9.4 Hz, lH), 4.30 (d,] = 9.0 Hz, lH), 3.85 (s, 3H), 3.82-3.69 (m, lH), 3.61 (ddd, 1 = 
15.1, 12.8,3.4 Hz, lH), 2.87 (s, 3H), 2.87 (s, 3H), 2.82-2.67 (m, lH), 2.36 (dt, 1 = 16.6, 
6.0 Hz, lH), 2.10 (ddd,] ~ 10.9, 2.3 Hz, lH), 1.86 (dt,] = 13.0,4.3 Hz, lH), 1.51 (dt,] ~ 
13.6, 2.6 Hz, lH); i3C NMR (CDCb, 150 MHz): 6 145.30, 142.94, 137.41, 129.80, 
129.04, 127.48, 122.83, 121.36, 111.45, 94.96, 93.82, 68.66, 55.97, 52.88, 48.47, 
42.19, 30.92, 29.39; LRMS-FAB (mjz): [M + H]+ 300 (23), M+ 299 (54), [M - OMe]+ 
268 (12), 136 (23), 91 (20), 73 (100),69 (26),57 (57), 55 (42),44 (30),43 (43),41 
(37); HRMS-FAB (mjz): M+ ealcd. for C18H2iN03: 299.1521, found 299.1523. 
N -(2-((5aS,6S,9'aR)-1-((1,3-Dioxolan-2-yl)methyl)-6-bydroxy-4-methoxy-
5a,6,7,9a-tetrabydrodibenzo[b,d]furan-9a-yl)ethyl)-N-methylacetamide 
(217). 
MeO 
217 
A solution of 214 (21 mg, 0.058mmol) in CH2Cb (1.5 mIl and pyridine (0.1 mI, 
1.239 mmol) was treated with AeC} (25 Ill, 0.352 mmol) at 4 DC. The suspension was 
stirred 2.5 h at 4 DC and 1 h at 25 DC, diluted with CH2Cb (10 ml) and washed with 
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1M HCl (6 ml), saturated aqueous NaHC03 solution (6 ml), and brine (6 ml), dried 
(MgS04), and evaporated. The crude diacetate was pure based on 1 H NMR spectrum 
and was used directly in the next step. A solution of crude diacetate in 0.12M 
solution of MeONa in MeOH was stirred for 4 h and treated with DOWEX 50WX8-
100(H+ form). Filtration, evaporation, and liquid chromatography (AcOEtjMeOH 
5:1) afforded 217 (20 mg, 87%) as a colorless oil. Rf (CH2ClzjMeOHjaqueous NH3 
100:10:1) 0.51; [a]D20 +17.5 (c 1.00, CHCb); IR (CHCb): n 3593 (w), 3024 (w), 3010 
(m), 2937 (m), 2896 (w), 2841 (w), 1732 (w), 1633 (s), 1584 (w), 1507 (m), 1463 
(w), 1439 (m), 1428 (m), 1402 (m), 1379 (w), 1362 (w), 1315 (w), 1280 (m), 1262 
(m), 1255 (m), 1167 (w), 1130 (m), 1091 (m), 1049 (m), 1017 (m), 980 (w), 944 
(w), 909 (w) cm-1; 1H NMR (CDCb, 300 MHz, 2 rotamers): 6 6.85-6.69 (m, 2H), 6.04 
(br. s, 0.6H), 6.01 (br. s, 0.4H), 5.85-5.72 (m, IH), 5.08-4.99 (m, IH), 4.56-4.49 (m, 
0.6H), 4.35 (d, ] = 8.5 Hz, 0.4H), 4.03-3.79 (m, IH), 7H), 3.65-3.59 (m, 0.6H), 3.40-
3.26 (m, 1.4H), 3.10-2.78 (m, 6H), 2.47-2.29 (m, IH), 2.21-1.78 (m, 3H), 2.00 (s, 
1.7H), 1.95 (1.3H). 13C NMR (CDCb, 150 MHz, 2 rotamers): 6170.49, 170.39, 145.76, 
145.59, 144.14, 144.06, 132.52, 131.73, 129.19, 128.91, 125.58, 125.18, 124.74, 
124.53, 124.17, 123.77, 111.90, 111.72, 104.62, 104.60,90.75, 90.05, 67.90, 67.86, 
65.11, 65.05, 56.02, 55.97, 55.95, 51.74, 51.65, 46.84, 44.10, 38.39, 36.51, 36.48, 
36.46, 36.37, 33.41,21.94,21.06; LRMS-EI (mjz): M+403 (1.1), 122 (18), 102 (18), 
101 (27), 100 (16), 86 (11), 85 (16), 83 (23), 80 (100), 73 (35), 44 (14), 43 (50); 
HRMS-EI (mjz): M+ caled. for C22H29N06: 403.1995, found 403.2000. 
94 
N-(2-((2S,2a1R. 5aS)-2-Hydroxy-7 -methoxy-5-oxo-1,2,2a,2a1,5,5a-
hexahydrophenanthro[ 4,5-bcd] furan'-2a1-yl)ethyl)-N-metbylacetamide (218). 
218 
A suspension of 217 (30 mg, 0.074 mmol) and IBX (31 mg, 0.11 mmol) in AcOEt (2 
ml) was stirred at 80°C for 4 h, cooled to 25°C, filtered through Celite (washing 
with AcOEt), and evaporated to get crude ketone (15 mg) which was used in the 
next step without further purification. Rf (AcOEtjMeOH 10:1) 0.30. 
A solution of crude ketone (15 mg, 0.037 mmol) in toluene (1 ml) was treated with 
50% aqueous TFA (0.3 ml), the mixture was stirred at 50°C for 4 h, concentrated, 
and the residue extracted with CH2Clz (3 x 15 ml). The combined organic layers 
were washed with saturated aqueous NaHC03 solution (1 x 2 ml), brine (1 x 2 ml), 
dried (MgS04), filtered, and evaporated. Flash column chromatography 
(CH2Clz/MeOH/aqueous NH3 92:8:1) afforded a mixture of alcohols 218 (3 mg,22% 
from 217). Rf (AcOEtjMeOH 5:1) 0.33; IR (CHCb): n 3606 (w), 3386 (w), 3021 (w), 
3006 (w), 2934 (w), 1799 (w), 1730 (w), 1686 (m), 1631 (s), 1508 (m), 1453 (m), 
1439 (m), 1413 (m), 1363 (w), 1283 (m), 1265 (m), 1159 (w), 1092 (w), 1035 (m), 
908 (m) cm-1; lH NMR (CDCb, 600 MHz, 1:1 mixture of 2 diastereoisomers): l) 7.13 
(dd,j = 10.8, 3.0 Hz, 0.5H), 7.07 (dd,j = 10.2,4.2 Hz, O.5H), 7.01 (dd,j = 10.4,4.0 Hz, 
IH), 6.75-6.60 (m, IH), 6.19 (dd,j = 10.8, 3.0 Hz, 0.5H), 6.14 (dd,j = 10.2, 1.9 Hz, . 
0.5H), 6.10 (dd,j = 10.4, 2.1 Hz, IH), 4.82 (s, IH), 4.78, 4.76 (2s, IH), 3.88, 3.85 (2s, 
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3H), 3.87 (5, 3H), 3.83-3.72 (m, 2H), 3.20-2.75 (m, 12H), 2.10-2.00 (10H); LRMS-EI 
(mjz): M+ 357 (3), 304 (13), 303 (17), 257 (22), 251 (10), 240 (14), 239 (23),227 
(19),211 (10), 115 (10), 101 (67), 100 (61),87 (10),86 (81), 84 (61), 75 (25), 73 
(68),58 (30), 57 (19),56 (13), 55 (13),51 (11),49 (26),47 (31),45 (18),44 (100), 
43 (68),42 (24),41 (13); HRMS-EI (mjz): M+ caled. for C2oH23NOs: 357.1576, found 
357.1571. 
N-(2-((SaS,6S,9aR)-1-((1,3-dioxolan-2-yl)methyl)-6-hydroxy-4-methoxy-
Sa,6,7,9a-tetrahydrodibenzo [b,d] furan-9a-yl) ethyl)-N-methyl -2,4-
dinitrobenzenesulfonamide (219). 
MeO 
219 
A solution of secondary amine 214 (61 mg, 0.17 mmol) in CH2Ch (1.5 ml) was 
treated with iPr2NEt (35 ""I, 0.203 mmol) and dinitrobezenesulfonyl chloride (50 
mg, 0.19 mmol) and stirred for 20 min. The reaction mixture treated with water (1 
ml) and extracted with CH2Ch (3 x 10 ml). The combined organic layers were 
washed with saturated aqueous Na2C03 solution and brine, dried (MgS04), filtered, 
and evaporated. Flash column chromatography (hexanesJAcOEt 1:1) afforded 
sulfonamide 219 (51 mg, 51 %) as a yellow oil. Rf (hexanesJ AcOEt 1:1) 0.35; [a]D20 = 
+8.34° (c 1.0, CHCh); IR (CHCh): n 3592 (w), 3029 (w), 2983 (w), 2893 (w), 1731 
(w), 1556 (5), 1541 (5), 1366 (5), 1351 (5), 1279 (m), 1165 (5), 1131 (m), 1049 (5), 
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946 (m) cm-1; 1H NMR (CDCb, 600 MHz): 68.47 (dd,} = 6.6.,2.2 Hz, IH), 8.45 (d,} = 
2.4 Hz, IH), 8.10 (d,} = 8.5 Hz, IH), 6.86 (d,}=8.4 Hz, IH), 6.79 (d,}=8.4 Hz, IH), 6.04 
(dd,] = 10.1, 1.7 Hz, IH), 5.86-5.83 (m, IH), 5.05 (dd,} = 6.3, 3.5, IH), 4.39 (d,] = 8.4, 
IH), 4.03 (ddd,} = 15.5, 10.1, 7.4, 2H), 3.92-3.85 (m,3H), 3.87 (s, 3H), 3.41-3.35 (m, 
IH), 3.01 (dd,} = 14.5,3.5, IH), 2.96-2.91 (m, IH), 2.93 (s, 3H), 2.89 (dd,] = 14.5,6.4, 
IH), 2.40 (dt,] = 17.4, 5.4, IH), 2.16-2.11 (m, 2H), 1.99 (td,} = 12.1, 4.7, IH); 13C 
NMR (CDCh, 75 MHz): 6149.60, 148.05, 145.46, 144.07, 137.93, 132.58, 131.61, 
128.47, 126.03, 125.72, 124.60, 124.03, 119.72, 111.80, 104.39, 90.24, 67.77, 64.99, 
64.94, 55.87, 51.50, 46.38, 37.64, 36.33, 29.31; LRMS-EI (m/z): M+ 591 (12), 147 
(16), 136 (24), 91 (14), 89 (14), 77 (13), 73 (100); HRMS-EI (m/z): M+ cald. for 
C26H29N3011S: 591.1507, found 591.1522. 
N-(2-((5aS,9aR)-1-((1,3-dioxolan-2-yl)rnetbyl)-4-rnetboxy-6-oxo-5a,6,7,9a-
tetrahydrodibenzo [b,d] furan-9a-yl) etbyl)-N-rnetbyl-2,4-
dinitrobenzenesulfonarnide (220) 
220 
A suspension of alcohol 219 (64 mg, 0.11 mmol) and IBX (45 mg, 0.16 mmol) in 
AcOEt (3 ml) was stirred at 80 °Cfor4 h, cooled to 25°C, and filtered through Celite 
(washing with AcOEt) affording crude 220 (60 mg) which was used without further 
purification. Rf(hexanes/AcOEt 1:1) 0.23; IR (CHCb): n 3101 (w), 3032 (w), 2981 
97 
(w), 2893 (w), 1738 (m), 1556 (s), 1541 (s), 1508 (m), 1366 (s), 1351 (s), 1283 (m), 
1164 (s), 1131 (m), 1044 (m), 908 (s) cm-1; lH NMR (CDCh, 600 MHz): B 8.49 (dd,J = 
8.6,1.9 Hz, lH); 8.44 (d,J= 1.9 Hz, lH), 8.15 (d,J= 8.6 Hz, lH), 6.85 (d,J=8.4 Hz, lH), 
6.77 (d, J=8.4 Hz, lH), 6.03 (d, J = 9.9 Hz, lH), 5.87 (ddd, J = 10.0, 3.9, 3.9 Hz, lH), 
5.02 (dd,J = 5.6,4.1, lH), 4.81 (s, lH); 4.00-3.96 (m, 2H), 3.92-3.84 (m, 2H), 3.87 (s, 
3H), 3.40-3.35 (m, lH), 3.09 (ddd,J = 19.31, 3.86, 1.99, lH), 3.07-3.02 (m, 2H), 2.96-
2.93 (m, lH), 2.94 (s, 3H), 2.30-2.22 (m, 2H); 13C NMR (CDCh, 150 MHz): B 203.68, 
149.70, 148.09, 146.74, 143.84, 137.65, 132.65, 129.82, 128.73, 126.17, 124.71, . 
124.53, 124.12, 119.77, 112.67, 104.37, 87.68, 64.99, 64.97, 57.38, 56.17, 46.37, 
37.30,36.86,36.14,35.05; LRMS-EI (mjz): M+ 591 (12), 147 (16), 136 (24),91 (14), 
89 (14), 77 (13), 73 (100); HRMS-EI (mjz): M+ caled. for C26H29N3011S: 591.1507, 
found 591.1522. 
(2a2R,6aS, 9aS)-5-Methoxy-2a2-(2-(N -methyl-2,4-
dinitropbenylsulfonamido )ethyl)-7 -oxo-1,2,2a2,6a, 7, 9a-
bexabydropbenanthro[ 4,5-bcd]furan-1-yl metbanesulfonate (221). 
221 
A solution of crude 220 (15 mg, 0.025 mmol) in toluene (1 ml) was treated with 
50% aqueous TFA (0.14 ml) and the biphasic mixture was stirred at 50°C for 2 h. 
The volatiles were removed in vacuo, the residue was dissolved in CH2Cb (1 ml) and 
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treated with iPr2NEt (5.0 ~l, 0.038 mmol) and MsCI (2.4 ~l, 0.031 mmol) at 0 °C. The 
mixture was stirred for 30 min at 0 °C, treated with saturated aqueous NH4CI 
solution (1 ml) and extracted with CH2CI (3 x 5 ml). The combined organic layers 
were washed with brine, dried (Na2S04), filtered, and evaporated. Flash column 
chromatography (CHCb/EtOAc 3:1) afforded 221 (1 mg, 6 %). The lH NMR 
spectrum was identical to one reported in the literature.97 
Rf (hexanes/AcOEt 1:3) 0.51; lH NMR (CDCb, 600 MHz): 6 8.49-8.44 (m,2H); 8.08 
(d,J= 8.4 Hz, lH),6.90 (dd,J= 10.3,4.0 Hz, lH),6.77 (d,J=8.6 Hz, lH),6.73 (d,J=8.6 
Hz, lH), 6.20 (dd,J= 10.6,2.3 Hz, lH),4.86 (s, lH), 3.88 (s, 3H), 3.51-3.43 (m,lH), 
3.23-3.18 (m, lH), 3.16 (s, 3H), 3.16 (s, lH), 3.12-3.09 (m, lH), 2.94 (s, 3H), 2.89-
2.87 (m, lH), 2.26-2.18 (m, 2H). 
N-(2-((2a1R, 5aS)-7-Methoxy-5-oxo-1,2a1,5,5a-tetrahydrophenanthro[4,5-
bcd]furan-2a1-yl)ethyl)-N-metbyl-2,4-dinitrobenzenesulfonamide (222) and 
N-(2-((2a1R, 5aS)-7-methoxy-5-oxo-2a1,4,5,5a-tetrahydrophenanthro[4,5-
bcd]furan-2a1-yl)ethyl)-N-methyl-2,4-dinitrobenzenesulfonamide (223). 
222 223 
A solution of crude 220 (10 mg) in toluene (1 ml) was treated with 50% aqueous 
TF A (0.1 ml), and the biphasic mixture was stirred at 50°C for 2 h. The volatiles 
were removed in vacuo, the residue was dissolved in CH2Clz (1 mI), cooled to 0 °C, 
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treated with iPrzNEt (12 Ill, 0.085 mmol) and MsCI (5.0 Ill, 0.077 mmol), and stirred 
for 30 min. The reaction mixture was treated with saturated aqueous NH4CI 
solution (1 ml) and extracted with CH2Ch (3 x 5 ml). The combined organic layers 
were washed with brine, dried (Na2S04), filtered, and evaporated. Flash column 
chromatography (CHCb/ AcOEt 3:1) afforded 222 (3 mg, 33% from 219) and a 
mixture of222/223::: 1:1.5 (2 mg, 22% from 219). 
Data for 222: Rf (CHCb/AcOEt 2:1) 0.47; IR (CHCb): n 3101 (w), 3026 (w), 3012 
(w), 2961 (w), 2930 (w), 1784 (w), 1730 (m), 1686 (m), 1641(w), 1604 (w), 1556 
(s), 1541 (s), 1506 (m), 1455 (w), 1440 (w), 1367 (s), 1350 (s), 1265 (m), 1235 (m), 
1162 (s), 1102 (s), 1046 (m), 1008 (m), 963 (w), 950 (w), 905 (w) em-I; IH NMR 
(CDCb, 600 MHz): 6 8.47-8.43 (m, lH), 8.07 (d,] = 7.9 Hz, lH), 7.26 (lH overlapped 
with a signal of residual CHCb), 6.75 (d,] = 7.9 Hz, lH), 6.71 (d,] = 7.9 Hz, lH), 6.40 
(d,] = 7.2 Hz, lH), 5.98 (d,] = 10.2 Hz, lH), 4.99 (s, lH), 3.87 (s, 3H), 3.59 (d,] = 20.0 
Hz, lH), 3.46-3.38 (m, 2H), 3.14-3.07 (m, lH), 2.91 (s, 3H), 2.19 (td,]::: 12.1,4.9 Hz, 
lH), 2.11 (td,] ~ 12.1, 3.8 Hz, lH); 13C NMR (CDCb, 150 MHz): 6 193.43, 149.89, 
148.26, 145.34, 143.24, 139.20, 137.70, 131.26, 126.36, 143.96, 133.51, 131.26, 
126.22, 120.51, 119.93, 113.95, 125.28, 86.86, 56.84, 47.91, 46.70, 37.67, 35.28, 
30.65; LRMS-EI (m/z): M+ 527 (9), 266 (32),252 (22),251(56),250 (21),240 (65), 
239 (55),238 (62), 235 (26),231 (21),225 (54),223 (54),211 (25), 168 (44), 152 
(24),139 (41), 76 (42), 75 (50),74 (27), 64 (100),63 (34),51 (42),45 (44),44 (85); 
HRMS-EI (m/z): M+ caled. for C24H21N309S: 527.0998, found 527.1018. 
Data for 223: Rf (CHCb/AcOEt 2:1) 0.53; IH NMR (CDCb, 600 MHz, mixture of 
222/223 ~ 1:1.3): 6 8.50-8.43 (m, overlapped with signals of 222, 2H), 8.14 (d,] = 
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9.1 Hz, 1H), 6.74 (d,] = 9.1 Hz, 1H), 6.69 (d,] = 9.1 Hz, 1H), 6.45 (d,] = 9.1 Hz, 1H), 
6.17 (d,] = 9.1 Hz, 1H), 5.77 (d,] = 7.2 Hz, 1H), 5.28 (s, 1H), 3.91 (s, 3H), 3.48,.3.36 
(m, overlapped with signals of 222, 2H), 3.30-3.20 (m, 1H); 2.92 (dd,] = 16.2, 7.2 Hz, 
partially overlapped with a signal of MeN of 222, 1H), 2.89 (s, 3H), 2.22-2.07 (m, 
overlapped with signals of 222, 2H). 
N-(2-((5aS,6~ 9aR)-1-(2,2-Dimethoxyethyl)-4-methoxy-6-oxo-5a,6,7,9a-
tetrahydrodibenzo[b,d1furan-9a-yl)ethyl)-N-methyl-2,4-
dinitrobenzenesulfonamide (224). 
MeO 
OMe 
224 
A solution of 219 (42 mg, 0.071 mmol) and pTsOH (6 mg, 0.04 mmol) in MeOH was 
refluxed for 3 d, cooled to 25°C, treated with with saturated aqueous NaZC03 
solution (2 ml), and extracted with CHzCh (3 x 10 ml). The combined organic layers 
were washed with brine, dried (NaZS04), filtered, and evaporated. Flash column 
chromatography (hexanes/ AcOEt 1:3) afforded dimethyl acetal 224 (36 mg, 86 %) 
as a yellow oil whose 1 H NMR spectrum was identical to that of its enantiomer 
reported in the literature.97 
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N-(2-((5aS, 9aR)-1-(2,2-Dimethoxyethyl)-4-methoxy-6-oxo-5a,6, 7, 9a-
tetrahydrodibenzo [b,d] furan-9a-yl)ethyl)-N-methyl-2,4-
dinitrobenzenesulfonamide (225). 
225 
A suspension of dimethyl acetal 224 (36 mg, 0.061 mmol) and IBX (25 mg, 0.91 
mmol) in AcOEt (2 mI) was stirred at 80°C for 3 h. The reaction mixture was cooled 
to 25°C and filtered through Celite (washing with AcOEt) affording crude ketone 
225 (33 mg, 91 %) as a yellow oil which was used in the next step without further 
purification. Rf (hexanes/AcOEt 1:1) 0.35; [a]n20 = +25.5° (c 1.0, CHCb); IR (CHCb): 
2982 (w), 2936 (w), 1731 (5), 1556 (m), 1541 (m), 1507 (w), 1374 (m), 1351 (m), 
1267 (m), 1164 (m), 1046 (5),908 (5) cm-l; lH NMR (CDCb, 300 MHz): 88.49 (dd,] = 
8.6,2.2 Hz, IH), 8.44 (d,] = 2.0 Hz, IH), 8.14 (d,] = 8.6 Hz, IH), 6.79 (d,j=8.6 Hz, IH), 
6.76 (d,]=8.6 Hz, IH), 6.03 (br d,] = 10.0 Hz, IH), 5.87 (ddd,1 = 10.0,3;9,3.9 Hz IH), 
4.82 (5, IH), 4.50 (t, ,] = 5.3 Hz, IH), 3.88 (5, 3H), 3.35 (5, 3H), 3.32 (5, 3H), 3.34 (m, 
IH), 3.17-3.01 (m, 3H); 2.94 (5, 3H); 2.86-2.83 (m, IH); 2.27-2.20 (m, 2H);13C NMR 
(CDCb, 75 MHz): 8 203.85, 149.77, 146.81, 143.79, 137.75, 132.77, 129.90, 128.96, 
126.29, 125.15, 124.60, 124.47, 119.90, 112.77, 105.60, 87.72, 57.59, 56.29, 54.43, 
53.70,46.50,37.43,36.77,35.99,35.14; LRMS-EI (mjz): M+ 591 (1),327 (3),270 (9), 
248 (100), 231 (55), 227 (10), 203 (19), 187 (5), 167 (25), 163 (7) 149 (72), 128 
102 
(69), 127 (51), 122 (38.9), 105 (57); HRMS-EI (m/z): M+calcd. for C26H29N3011S: 
591.1523, found 591.1531. 
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